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ABSTRACT 
 
Proventricular dilatation disease (PDD) is a fatal viral disease that affects mainly 
psittacine birds, although some non-psittacine species can be affected. Gastrointestinal 
and/or neurological signs can be seen in PDD-affected birds. These signs are likely a 
result of non-suppurative inflammation of the central, peripheral and autonomic nervous 
systems. Parrot bornavirus (PaBV) was discovered as a causative agent of PDD in 2008. 
The prognosis of PDD is very poor once clinical signs have developed and no specific 
treatments or commercial vaccines are available to date. 
 
In order to investigate methods of protection, we vaccinated cockatiels using inactivated 
whole PaBV and/or recombinant PaBV N protein vaccines followed by challenge with 
virulent PaBV-2. In the first experiment, inactivated PaBV-2-infected cells were 
administrated via intramuscular (IM) inoculation, three times, followed by one IM 
injection of recombinant N protein vaccine. In a second experiment, the recombinant N 
protein vaccine was administered alone, two times, via the IM route. Over 28 weeks post 
challenge, cloacal swabs were collected and body weights and any clinical signs were 
noted. Using tissues collected at necropsy, histopathologic examination was used to 
detect the presence of microscopic lesions characteristic of PDD. Quantitative Real-
Time PCR (qRT-PCR) and immunohistochemistry (IHC) were used to detect PaBV-
RNA and antigen respectively. Using western blots assays, we were not able to detect a 
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humoral response after vaccination with the inactivated vaccine. Conversely, the 
recombinant N protein vaccine stimulated production of anti-N antibodies.  
 
The results of both vaccine studies indicated that the recombinant N protein vaccine was 
able to protect subsequently challenged birds from lesions associated with PDD. Further, 
the vaccine protected birds from PDD-related morbidity and mortality. However, the 
vaccine did not protect "efficiently" against infection, as PaBV- RNA and antigen were 
detected in organs and cloacal swabs of vaccinated and unvaccinated birds. Moreover, 
there was no evidence that vaccination, either before or after challenge, increased the 
severity of the infection. We hypothesized that this protective response was a result of a 
switch from a type 1 cell-mediated immune response to a type 2 humoral immune 
response. This hypothesis was supported by a third study which revealed that treatment 
of cockatiels with cyclosporine A, an immunosuppressant, at the time of challenge with 
virulent PaBV-2, also conferred complete protection against PDD at the expense of 
increasing the viral load. This experiment showed that PDD might be an 
immunologically mediated disease, similar to Borna disease in mammals.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Proventricular Dilatation Disease (PDD) 
PDD is a serious and devastating viral disease of captive parrots worldwide. It is 
typically characterized by the presence of lymphoplasmacytic infiltrates in central, 
peripheral and automatic nervous tissues. PDD was first recognized in the late 1970s and 
early 1980s in the Unites States and Germany during outbreaks which affected macaws 
(Ara spp.). The disease was initially named macaw wasting disease [1] and other names 
for the disease include macaw fading disease, infiltrative splanchnic neuropathy and 
myenteric ganglioneuritis [2-4]. PDD has been reported in more than 50 psittacine 
species, but some non- psittacine species can also be affected [5, 6]. After the disease 
was first described, research was begun to identify and isolate the responsible etiological 
agent(s). It was widely accepted that the disease agent was a viral agent and several 
viruses were considered as candidates. These included a paramyxovirus [7], togavirus, 
picornavirus [8] and a coronavirus [9]. However, further studies were unable to link 
these viruses with PDD and the fulfillment of Henle-Koch’s postulates was not achieved 
[9-11]. In 2008, using pyrosequencing, a pan viral microarray approach and 
conventional PCR, two independent research groups isolated and identified a novel 
bornavirus from PDD- positive parrots and called it avian bornavirus. This new virus 
had <70% shared sequence at the nucleotide sequence level and <80% at the overall 
amino acid level with BoVD-1, a mammalian bornavirus. [12, 13].   
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PDD causes severe non- suppurative inflammation of the autonomic nervous system 
which innervates the myenteric ganglia of the gastrointestinal tract (GIT). Esophagus, 
crop, proventriculus and ventriculus are the most affected parts of the GIT. The 
neurological function of the myenteric ganglia is impaired and as a result, and the 
peristaltic movement of the GIT is impaired or lost. Consequently, food accumulates in 
the proventriculus, leading eventually to crop stasis and enlargement and dilatation of 
the proventriculus and intestine. Several clinical signs may occur as a result. These 
include anorexia, lethargy, passage of undigested food with fecal material, regurgitation, 
diarrhea, dysphagia, emaciation leading to cachexia, and vomiting. Death is often due to 
starvation and sometimes is caused by sepsis as a result of microbial overgrowth in the 
enlarged non-motile proventriculus [14-16]. Non-purulent inflammation of the CNS [1, 
17], can cause neurological signs such as depression, ataxia, tremor, incoordination, 
blindness and seizures [1, 18]. These signs may occur alone or in parallel with clinical 
signs of a dysfunctional digestive tract [1, 19-21]. Mortality may reach 100% [1]. 
 In general, clinical signs and symptoms of PDD, as in Borna disease in horses and 
sheep, are not specific (pathognomonic) for this disease. Definitive diagnosis is based on 
postmortem histopathological examination to reveal infiltration of lymphocytes and 
plasma cells in the myenteric ganglia of the proventriculus and ventriculus [6, 22]. Most 
cases also show non-purulent encephalomyelitis and ganglioradiculoneuritis of the spinal 
nerves. Inflammation of peripheral nerves and gliosis may also occur [10, 11, 14, 15, 18, 
23]. Cardiac problems due to conduction system deficiency of some PDD- affected birds 
might be a cause of sudden death [17]. 
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 Crop biopsies can be used as a useful confirmative intra-vitam diagnostic tool 
(especially for expensive or highly endangered birds) to reveal the presence of a 
lymphoplasmacytic infiltration in the myenteric ganglia. However, the segmental 
distribution of lesions decreases the accuracy of this method. Radiography, such as X-
ray and contrast imaging using barium can also be used to detect the presence of an 
enlarged proventriculus [24, 25].  Several serological techniques such as western blot 
(WB), indirect immunofluorescence assay (IFA) and enzyme-linked immunosorbent 
assay (ELISA) can be used to detect the presence of specific antibodies against the 
causative agent, PaBV. However, negative results are not a helpful diagnostic indicator 
as many symptomatic birds lack detectable antibodies to PaBV [20, 26]. Molecular 
techniques such as reverse transcription polymerase chain reaction (RT-PCR) assays can 
be used to detect viral sequences in tissues, feces, cloacal and/or crop swabs as well as 
feather calami [27]. A positive PCR result in the feces is an indication of current 
infection; however, a negative result is inconclusive as it is well documented that virus 
shedding is intermittent [25]. Repeated testing of multiple samples can be helpful, as can 
using a combination of serology and PCR which together are considered to be the most 
dependable diagnostic approaches. Unfortunately, neither of these diagnostic tools 
(alone) is highly reliable in detecting infection. In addition, neither is helpful in 
predicting outcome, as many infected birds remain healthy for many years and die of 
other causes. There is no single noninvasive test that is entirely suitable for the diagnosis 
of PaBV infection [27-29].  
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For postmortem diagnosis, typical histopathologic lesions can be found primarily in GIT 
and CNS. Viral RNA can be detected in the GIT and nervous system and often in other 
tissues. Viral antigen can be detected by immunohistochemistry (IHC) using antibodies 
to PaBV nucleoprotein (N) or phosphoprotein (P). Duck embryo fibroblast (DEF) or 
quail cell lines CEC-32 and QM7 can be used to isolate the virus [28, 30, 31] 
 
Parrot Bornavirus (PaBV)  
PaBV (previously known as avian bornavirus, ABV) was first discovered in 2008 when 
independent research groups from the United States detected a novel borna virus among 
several PDD- positive birds by using pyrosequencing [13] and micro array approaches 
[12]. The virus was named avian borna virus because it is shared several features 
characteristic of the Bornaviridae family (Order Mononegavirales) but less than 70% 
nucleotide sequence identity with mammalian Borna virus BoDV-1 [30, 32]. To date, 
eight bornavirus genotypes have been identified from psittacines (PaBV 1-8) and seven 
from nonpsittacine birds. These include strains isolated from Canada geese, trumpeter 
swans, canaries and estrilid finishes [12, 13, 16, 33-39]. The family Bornaviridae 
currently contains one genus, Bornavirus, which includes five species: Mammalian 1 
bornavirus which includes BoDV-1 and 2; Psittaciform 1 bornavirus which includes 
PaBV1,2,3,4 and 7; Passeriform1 bornavirus which includes the strains isolated from 
canary birds and Bengalese finches; Passeriform 2 bornavirus which includes an isolate 
from an estrilid finch and Waterbird 1 bornavirus which includes isolates from Canada 
geese, mute swans and a variety of ducks. PaBV 1-4 and 7 have all been isolated from 
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parrots and identified as causative agents of PDD [32, 40]. PaBV- 5, 6 and 8 are not yet 
officially classified but have been isolated from birds diagnosed with PDD [41]. Another 
bornavirus has recently been isolated from Loveridge’s garter snake. This virus belongs 
to a novel species (Elapid 1 bornavirus) and is named Loveridge’s garter snake 1virus 
(LGSV-1). Because of insufficient characterization, this virus has been placed in the 
family Bornaviridae but not in the genus Bornavirus [32]. In 2015 a novel bornavirus 
was linked to three cases of human fatal encephalitis in three squirrel breeders in 
Germany [42].Genetic analysis revealed that this virus is less than 77% homology with 
mammalian 1 Bornavirus cluster [42]. 
 
Before the discovery of PaBV in 2008, the only known member of the family 
Bornaviridae was the mammalian Borna disease virus, BoDV-1, the causative agent of 
Borna disease of mammals, especially horses and sheep. Various isolates of this virus 
show very high sequence conservation, an uncommon feature among RNA viruses [12, 
43]. In contrast, PaBV is more divergent and to date, 8 different genotypes of this virus 
have been recognized [32, 41]. PaBV 2 and 4 are the most predominant worldwide [18, 
30]. Co-infection with more than one strain has frequently been noted; it appears that the 
severity of disease and the lesions in a co-infection do not significantly differ from those 
in a single infection [6, 34, 44]. 
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 Genome Organization  
Bornaviruses are enveloped, 80-100 nm in diameter, spherical viruses containing a 
single- stranded, non-segmented negative sense (NNS) RNA genome of about 8.9 kb. 
The bornavirus genome is considered the smallest among NNS viruses [31, 45]. Unlike 
other families of the order Mononegavirales (Paramyxoviridae, Rhabdoviridae and 
Filoviridae), bornavirus transcription and replication take place in the nucleus of host 
cells. Therefore, the splicing machinery of the host cell allows for alternatively spliced 
transcripts for protein expression [46, 47]. Short heterogenous untranslated regions 
(UTR) are located at the 3’- and 5’- ends of the bornaviral genome. These UTRs contain 
promoter elements for the transcription and replication of the genome. These UTRs 
differ from those of other NNS viruses in which UTR sequences (up to 20 nucleotides) 
are complementary to each other [47-50]. Moreover, the bornavirus genome, in contrast 
to other NNS RNA viruses, lacks specific, repetitive intergenic regions; instead, it has 
overlapping open reading frames (ORFs) [51, 52]. Bornaviral genomes contain three 
transcription units (III), defined by three different transcription initiation sites (S1-S3). 
Four polyadenylation signals/termination sites (T1-T4) (Fig1) have been identified and 
some transcripts are formed by read-through of these termination sites. In fact, the pol 
transcript is produced only by read-through of the T3 site [53]. Mammalian and parrot 
Borna viruses share the same general genome organization in terms of gene order, 
number of genes and organization of sites for initiation and termination of transcription 
[12, 13]. However, there are minor differences in the region between the N and X genes. 
BoDV-1 contains a regulatory element for synthesis of the X protein that is lacking in 
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most of the avian bornaviruses[12, 34, 54]. In fact, among the avian bornaviruses the 
N/X intergenic region is the most variable region of the genome. Neither the importance 
of these differences, nor mechanisms for regulation of X protein synthesis have been 
carefully examined for PaBVs. The Bornaviral ribonucleoprotein (RNP) complex is 
composed of N and P in association with genomic RNA [55, 56]. Both arms of immune 
system, humoral and cellular, recognize the nucleoprotein and to lesser extent the 
phosphoprotein as major targets [57]. 
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Figure 1. Borna disease virus genome organization. Conservation of genome 
organization, regulatory sequences, and protein domains of Borna disease virus (BDV) in novel 
strains from parrots 1034, 1322, and 1367. N, nucleoprotein; P, phosphoprotein; X, X protein; 
M, matrix protein; G, glycoprotein; L, L-polymerase protein. Genome regions not yet sequenced 
in the novel strains are shaded. P-bind, binding site for P on X; NLS, nuclear localization signals 
of X and P; PKC, protein kinase C epsilon phosphorylation sites in P; CK II, casein kinase 
phosphorylation sites in P; SIG, signal peptide; Furin, furin cleavage site; TM, transmembrane 
anchor of G; A – D, conserved RNA-dependent RNA polymerase motifs. Conserved 
sites/residues with respect to BDV strain V are shown in black; divergent sites/residues are 
indicated in red; K32 in P NLS-1 is divergent only in 1034/1322, K35 in NLS-1 and K183 in 
NLS-2 are divergent only in 1367. S2 and S3, start sites of transcription units 2 and 3, 
respectively, showing the conserved GAA initiation triplet; T1, T2, and T3, transcription 
termination sites showing the conserved TA6 consensus sequence; (t6) indicates a nonconserved 
TA6 sequence found in some BDV isolates. Blue bars indicate the 6 clusters represented by 
contigs obtained through pyrosequencing. Consensus splice site sequences corresponding to 
established introns I and II in genes for M and G of BDV strain V are aligned to corresponding 
sequences of the novel strains.   
This figure was adapted from reference [13] 
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Bornavirus Proteins 
The bornavirus genome encodes for at least six proteins. Starting at the genomic 3′ end, 
the gene order is: nucleoprotein (N), X-protein (X), phosphoprotein (P), matrix protein 
(M), membrane glycoprotein (G), and the RNA polymerase (L) [58, 59]. 
Glycoprotein (G): G encodes a 56-kDa polypeptide, however, a 94 kDa protein (gp 94) 
results from posttranslational modification through N-glycosylation with high- mannose 
oligosaccharide complexes [60-64]. This protein may play a crucial rule in persistence of 
bornaviral infection by protecting the antigenic epitopes through mimicking host N-
glycans [65]. G is cleaved into N-(GP-N, 51 kDa) and C-( GP-C, 43kDa) terminal 
subunits by cellular furin- like proteases [60, 62]. Only cleaved G has been detected in 
virus particles [65]. GP-N is sufficient for virus entry into cells via a receptor recognition 
mechanism. GP-C, on the other hand, might be needed for fusion, which occurs after 
internalization of the virus through endocytosis [66, 67].  
 
Matrix protein (M): M is a 14.5-kDa protein (142 amino acids).  M is the smallest matrix 
protein among NNS viruses. M forms noncovalently linked tetramers to serve as the 
bornavirus matrix protein [68, 69]. This protein plays a major role in particle formation. 
M can bind to P and thus is part of the viral RNP complex [70].  
Unlike other matrix proteins of NNS RNA viruses, bornaviruses M does not appear to 
interfere with polymerase activity [70, 71].   
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Nucleoprotein (N): N is the major component of the RNP complex which in turn acts as 
a template for the L [51, 72]. In the case of BoDV-1, 371 amino acid N, is found in two 
forms, 40-kDa (p40) and 38kDa (p38) [51, 52, 73]. In contrast to BoDV-1 N, the smaller 
(p38 kDa) form of N has not been identified for the avian bornaviruses., BoDV-1 p40 
contains a nuclear localization signal (NLS; P3KRRLVDDA11) and a nuclear export 
signal (NES; 128LTELEISSIFSHCC141) [29, 74, 75]. Both are important for movement 
of the ribonucleoprotein (RNP) complex into and out of the nucleus [51, 52, 56]. These 
roles are compatible with the distribution of N isoforms in infected cells, with p40 
primarily found in the nucleus and p38 primarily found in the cytoplasm [51, 52]. 
Although p38 can accumulate in the nucleus at levels similar to p40, it cannot alone 
support the transcription/replication process of the bornaviral genome. This  suggests 
that the amino terminal sequence of p40 may have functions in addition to RNP 
translocation [76]. Co-localization and purification experiments indicate that p40 and 
p38, as well as P and M, associate with genomic RNA to form the RNP complex [70, 
71]. [55, 72, 77]. Encapsidation of genomic RNA by multimeric N does not protect 
genomic RNA against enzymatic attack [78, 79].  
 
Phosphoprotein (P): P is a 24 kDa, 201 amino acid protein that plays an important role in 
the replication cycle of bornaviruses. P acts as a transcriptional activator by binding and 
interacting with other viral proteins (X, N, M, and L) and with itself [64, 77, 80, 81]. P 
plays a pivotal role as a mediator for regulation and assembly of the polymerase 
complex [77]. P has two NLS and one NES [82, 83]. Infection of neurons by 
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bornaviruses results in interference with the recycling process of synaptic vesicles by 
blocking protein kinase C (PKC) -phosphorylation of key substrates. Evidence indicates 
that P plays a role in bornavirus pathogenesis by acting as a decoy substrate for 
phosphorylation by PKC within infected neurons [84, 85].  
 
L protein: L, the RNA dependent RNA polymerase, is by far the largest protein of 
bornaviruses (190 kDa, 1711 amino acids). This protein is translated from a spliced 
mRNA  [63, 86]. Nuclear localization of this protein in infected cells is achieved by an 
NLS motif (R844VVKLRIAP852) positioned in the center of this protein, or by 
interaction with P [87]. Bornavirus L contains conserved domains and motifs found in 
other NNS viral L proteins [48, 88].  
 
X protein: X is a nonstructural protein whose ORF overlaps the P ORF. X is the smallest 
bornaviral protein (10 kDa, 87 amino acids residues). Although X is not found in 
infectious particles, it plays an important role in the bornavirus replication cycle. 
Bornavirus genomes with nonfunctional X ORFs are not viable [89, 90]. Assembly of an 
active polymerase complex depends on the relative abundance of X and P in infected 
cells [91, 92]. X can be identified in both nuclear and cytoplasmic compartments. 
Nucleocytoplasmic shuttling of X protein can be achieved via its interaction with P [70, 
71, 93].The P interaction site has been mapped to amino acids 3-16 
(SDLRLTLLELVRRL), at the N-terminus of X. This sequence partially overlaps an 
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importin-binding sequence mapped to amino acids 6-19 (RLTLLELVRRNGN) of X and 
important for nuclear shuttling [94-96]. 
 
Bornavirus Replication Cycle 
To date, our understanding of the replication cycle and of PaBV is largely based on 
results of intensive research on BoDV-1 [54, 97, 98]. BoDV-1 attachment and entry 
seem to be comparable to rhabdoviruses and filoviruses, with pH-dependent entry 
through intracellular vesicles [99-101]. The BoDV-1 surface glycoprotein complex (GP-
N & GP-C) plays an important role for receptor recognition and cell entry. BoDV- 1 is 
believed to enter the cells by means of receptor-mediated endocytosis with the help of 
unknown surface receptors on infected cells [66, 102]. Interactions between bornavirus 
G and the cellular receptor triggers the internalization of the virus via an energy-
dependent mechanism using a clathrin-mediated (caveola-independent) pathway which 
requires the Ras-related protein Rab5 and microtubules [66, 103]. GP-N is the receptor 
binding protein while the hydrophobic amino-terminus of GP-C is required for pH- 
dependent membrane fusion in the endosome [61, 65, 103]. Fusion results in release of 
the viral RNP into the cytoplasm of infected cells [66]. However, no data are available 
concerning intracellular trafficking of the released RNP after membrane fusion [31]. 
Genome replication and transcription occur within the nucleus of infected cells. Thus, 
after translation, several viral proteins (N, P, X and L) move back into the nucleus via 
NLS. These proteins also have NES that may facilitate movement of newly assembled 
RNPs from the nucleus [56, 83]. Bornavirus N, P and L are required for viral genome 
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transcription and replication. Genomic RNA encapsidated by N protein acts as a 
template for the associated polymerase complex which consists of L and P. Even though 
X is not part of the RNP complex, it plays a major role in the replication cycle by 
modifying the formation and activity of the polymerase complex via interactions with P. 
Interactions of X and P results in changing the ratio of N to P, thus modifying the 
enzymatic activity of L [71, 76, 78, 93, 104]. Bornaviruses use mainly polycistronic 
mRNAs are transcribed from three transcriptional initiation sites [47, 53]. The only 
monocistronic product of the genome is a 1.2-kb transcript which is translated to 
generate the p40 and p38 isoforms of N [51, 52]. BoDV-1 packaging and release from 
infected cells are still not fully understood. Virions have been observed to bud from the 
plasma membrane of persistently infected cells in vitro [105, 106]. However, there is 
evidence of cell to cell spreading of the RNP complex [45]. Therefore, it seems that 
replication of bornaviruses in the central nervous system of susceptible hosts includes 
primary infection in which receptor-mediated endocytosis is followed by cell to cell 
propagation [107]. BoDV-1 can be detected, late in infection, in many tissues and organs 
as a result of its centrifugal spread via the axoplasm of peripheral neurons [108]. 
 
 
 
 
 
 
 14 
 
Pathogenesis and Pathogenicity  
The pathogenesis of PDD is still not fully understood even though it is well accepted that 
PaBV is the sole causative agent of this disease [12, 13, 23]. Many questions about PDD 
pathogenesis remain to be answered.  Many infected birds remain asymptomatic 
(clinically healthy) for long periods of time, sometimes for many years. The mechanisms 
and/or circumstances that trigger development of clinical disease are still not understood 
[109, 110]. PaBV is less restricted to neuronal tissues than BoDV-1, which is almost 
exclusively neurotropic and is seldom detected in other tissues [111, 112]. In PaBV-
infected, but healthy birds, the virus is most often detected in the brain while in clinically 
sick birds the virus is more widespread, present in many organs [30, 110]. It is not 
known if vigorous immune responses are the cause or the effect of more widespread 
tissue tropism. It is possible that the immune responses might be more vigorous in 
clinically diseased birds. Alternatively, differences in tissue distribution and 
pathogenesis might be a result of genotypic differences among PaBVs. [38, 54]. 
Another difference between BoDV-1 and PaBV is the route of inoculation. It has not 
been possible to infect rats with BoDV-1 using the intravenous route [113]. On the other 
hand, this method of inoculation was successful in cockatiels [114]. Thus, it is fair to 
suppose that PaBV and BoDV-1 share some parallel features of pathogenesis but that 
differences also might be present. 
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The pathogenesis of BoDV is attributed to immunopathological events in the CNS. In 
the absence of cytotoxic T lymphocytes (CTL), BoDV-1 can cause persistent non- 
cytopathic infection of the CNS and is present both in neurons and astrocytes [98, 115, 
116]. Transfer of T cells from clinically diseased rats to infected but clinically healthy 
rats initiates the development of Borna disease [23, 117, 118]. Thus, cellular damage 
occurs due to CD8 T lymphocytes, not directly by BoDV-1 [119]. In general, Borna 
disease is associated with infiltration of large numbers of immune cells into the CNS 
[120]. The severity of BoDV disease and the viral load in the CNS depends on the host 
age and species [120]. Persistent infection with high virus loads in the CNS has been 
found in neonatal rats. In contrast, adult immunocompetent rats develop 
meningoencephalitis [120]. CD8+ T cells play an important role in this scenario as the 
decline of BoDV 1– specific inflammation occurs when CD8+ T cell responses are 
reduced, despite continued virus replication [121]. CD8+ T cell play a key role for both 
virus- triggered clinical disease and antiviral defense activity. Virus- specific CD8+ T 
cell can provide protection against infection as a result of immunization. However, once 
a large number of neurons in the CNS become infected, the antiviral activities of CD8+ 
T cells become harmful [117, 118, 122, 123]. In addition to CD8+ T cells, CD4+ T cells 
also play a role in the pathogenesis of Borna disease. Establishing BoDV- specific T cell 
lines by using lymphocytes from N (p40)-immunized rats enabled researchers to select T 
helper lymphocytes bearing MHC class II and CD4. Passive transfer of these cells into 
BoDV infected, immunosuppressed healthy rats resulted in serious acute disease and 
death within 5 days post transfusion. However, transferring the same cells into 
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uninfected rats caused no disease. These results strongly indicate that this disease might 
be a result of delayed type hypersensitivity immune reaction (Type IV hypersensitivity) 
[118, 124-126].  
 
Innate responses to viral infections are multifaceted and complex. The complete picture 
of interactions of BoDV-1 with antiviral defenses is not clear. However, there is 
evidence that BoDV-1 evades innate responses by trimming the 5’ termini of genomic 
and antigenomic RNA. As a result of genome trimming, the RNA strands carry a 
terminal monophosphate, instead of a triphosphate. Thus (retinoic acid-inducible gene 1) 
(RIG-I) cannot sense the presence of virus in the infected cells; as a consequence, the 
production of type I interferon (IFN) is blocked [127, 128]. A study using PaBV infected 
quail cells lines showed that viral infection of cell cultures was reduced when type I IFN 
was added  [127], moreover, viral load in the cell cultures was reduced. In contrast, cell 
cultures with high viral load did not produce detectable levels of type I IFN. Another 
study showed that both PaBV and BoDV-1 X demonstrate similar type I IFN-inhibiting 
capacity, and the reduction in IFN is dose dependent upon X [129]. Kinetic analyses 
were used to compare the genomic termini during acute and persistent bornavirus 
infections and revealed that an accumulation of terminal truncations of one to three 
nucleotides at 3' terminus of the bornavirus genome resulted in attenuation of replication 
and transcription, probably contributing to lifelong, persistent infection [130]. Negative 
strand RNA virus genomes have ITRs that initiate synthesis of genomic and antigenomic 
RNA. Trimming of the bornaviral genome generates incomplete ITRs that are highly 
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attenuated as promoters for genome and antigenome synthesis [131]. In contrast, protein 
levels are not affected by incomplete ITRs. Therefore, complete ITRs appear to be 
important for genome replication but not for mRNA synthesis. This is compatible with 
bornavirus noncytolytic, persist infection where low levels of infectious virus particles, 
in combination with high antigen levels are observed [131]. It has been also shown that 
PaBV uses a similar mechanism (trimming the 5' terminus) to escape innate responses 
[127]. It has been suggested that bornaviruses might be used as novel RNA virus vectors 
for stable foreign gene expression in the CNS [132]. However, it is not known whether 
viral or host functions are responsible for genome trimming [31]. 
 
Genetically, BoDV is very homogeneous, with the exception of a strain named No/98, 
which differs by more than 15% at the nucleotide sequence level when compared to 
reference BoDV-1 strains [133]. However, variants that replicate better in mouse and rat 
models have been isolated. The consequences of divergent viral genotypes have not been 
of particular interest in studies of BoDV pathogenesis. In contrast, PaBV is much more 
genetically diverse. 
 
PaBV-4 and PaBV-2 genotypes are most commonly recovered from parrots with PDD 
[26, 133-135]. PaBV-2 appears to be more pathogenic for cockatiels than PaBV-4. 
Moreover, cockatiels experimentally infected with PaBV-2 develop mainly 
gastrointestinal signs whereas neurological signs were observed more frequently in 
PaBV-4 infected cockatiels [135]. 
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 Even though seroconversion in PaBV-2 infected cockatiels appears to occur earlier than 
in PaBV-4 infected cockatiels, the antibody titers are lower. Moreover, viral RNA 
shedding was detected later in PaBV-2 infected cockatiels than during PaBV-4 infection. 
In this experimental model, earlier immune responses may have limited PaBV-2 
replication but exacerbated disease [135]. 
 
In spite of less obvious clinical signs, viral loads in organs of PaBV-4 infected birds 
were significantly higher than in PaBV-2 infected birds. These results were independent 
of the route of inoculation (intracerebral or intravenous) and were also independent of 
the time point of death post infection. On the other hand, birds infected with PaBV-2 via 
the intracerebral route had higher viral loads compared with birds infected via the 
intravenous route. Therefore, these birds showed a clear depended in term of viral load 
in different organs with the route of inoculation as well as time point of death (late death 
birds had higher viral load in comparison with early death). Additionally, in PaBV-4 
infected birds, viral antigen was more frequently detected in the CNS in comparison 
with PaBV-2 infected birds, in which the levels of viral antigen were increased in the 
GIT [23, 135, 136]. Moreover, re-isolation of PaBV-4 was easier from almost all tissues 
compared to PaBV-2 infected birds. Re-isolation of virus from birds that died later 
required only one passage in cell culture, while virus re-isolation from birds that died 
earlier post infection required several passages. Finally, virus shedding was detected 
later in PaBV-2 compared to PaBV-4infected birds. These results demonstrate that 
neither the severity nor progress of the disease is correlated with the replication of the 
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virus. [136] Instead, disease is triggered through mechanisms independent of viral load. 
In fact, one explanation for these results is that early immune system activation reduces 
viral load at the expense of disease severity.  
 
It appears that the PaBV-2 infection may be similar to BoDV-1 infection in that even 
minimal virus replication triggers clinical disease, and disease progression is a result of 
T-cell responses [98, 135, 136]. These differences between infection patterns of PaBV-2 
and PaBV-4 might be the result of variations in genome sequence. It is also possible that 
there are virulent variants of PaBV-4 and benign varients of PaBV-2 [119, 136]. 
 More detailed study of PaBV replication, perhaps focusing on differences in G 
sequences and/or differences in X, are necessary to define the virulence determinants of 
these viruses. 
 
The immunopathogenic mechanisms of PaBV infection remain to be determined. In the 
case of BoDV, clinical disease depends largely on the development of immune responses 
[98, 135, 137]. Before the identification of PaBVs as the etiological agent of PDD in 
parrots, it was proposed by some that PDD might be an auto-immune disease similar to 
Guillain Barré syndrome in humans [138]. Rossi et al. (2008) claimed that the non-
purulent inflammation typical of PDD was a result of antiganglioside antibodies, and 
that these antibodies were significantly higher PDD- birds than in healthy birds [138]. 
Later, these authors concluded that these antibodies can be triggered as a result of PaBV 
infection, or any other viral infection. However, studies in our laboratory have revealed 
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no connections between clinical disease and the presence of antiganglioside antibodies 
[139]. We have attempted to induce PDD-like disease by inducing production of 
antiganglioside antibodies in chickens. (Leal et al Unpublished) reported that 
antiganglioside antibodies are not associated with the development of PDD. 
 
Tizard et al (2016) noted three potential events that could lead to proventricular 
dilatation in PDD. First: Excessive relaxation (or contraction failure) of smooth muscle 
fibers in the proventriculus as a result of prolonged stimulation of non-adrenergic non-
cholinergic (NANC) neurons in the myenteric plexus. Taking into consideration the 
destructive nature of the lesions of myenteric plexus as a result of bornavirus infection 
makes this scenario unlikely. Second: Obstruction of the so- called intermediate zone, 
located between proventriculus and the ventriculus, as a result of damage to pacemaker 
cells of the isthmus resulting from accumulation of ingesta in proventriculus. Third: 
Impairment of satiation signals from the proventriculus to the brain as a result of failure 
of vagus nerve afferent signals, so the affected birds might be continuing to eat. This is 
unlikely however to be the primary cause, as many PDD affected birds observed stopped  
eating early in the course of the disease [140].  
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Transmission of PaBV 
The natural mechanisms of PaBV transmission are unknown. This virus is frequently 
detected in crop and cloacal swabs, so the fecal- oral route of transmission has been 
proposed [18, 30]. It is well documented that PDD can develop in a flock after new 
PaBV- positive birds are mixed with resident birds [14], clearly indicating horizontal 
transmission. However, some investigators note that not all PaBV-negative birds become 
positive even when in direct contact with infected birds [38, 39]. Some researchers have 
demonstrated that mixing PaBV- experimentally infected cockatiels with non-infected 
cockatiels, results in deposition of PaBV on the skin and feathers of the non-infected 
birds but that their internal organs remain virus-negative [23]. The extent of fecal- oral 
PaBV transmission among birds remains an enigma, especially when negative birds 
remain negative after years of contact with positive PaBV- positive birds [110]. 
   
Vertical transmission of PaBV also has been investigated. In one study, several embryos 
tested positive for PaBV-RNA and these embryos were of psittacine parents positive for 
PaBV [141]. However, it is not possible to conclude that the embryos were effectively 
infected, as the assay method was for PaBV RNA, not infectious virus. PaBV- negative 
offspring can also be obtained from positive parents by hand rearing [142]. In order to 
prove vertical transmission, viable virus needs to be isolated from PaBV- positive eggs 
or from offspring hatched in incubators [141, 143].  
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In general, there are difficulties explaining PaBV transmission between birds whether 
horizontally or vertically. Part of these difficulties come from the nature of the virus 
itself since PaBV establishes persistent infections of cells, and these cells release very 
low numbers of infectious particles [30, 54]. It may be that just a few cell types, for 
example kidneys, are capable of releasing enough infectious particles for effective 
transmission [144].  
 
PaBV transmission is an area that needs to be extensively studied in well-controlled 
experimental systems. In a recent study, different routes of infection were assessed, as 
wells as different doses of infection, in order to determine the effectiveness of PaBV-2 
infection in cockatiels [145]. Mucosal routes of infection failed to establish persistent 
infection with PaBV-2 in cockatiels, in contrast to parenteral routes in which all the 
inoculated birds were infected [145]. 
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Seroconversion among Naturally and Experimentally Infected Birds 
PaBV- specific antibodies have been detected in both PDD- affected and asymptomatic 
birds [27, 146]. However, some infected birds never produce detectable antibodies. On 
the other hand, sudden seroconversion sometimes occurs just before the development of 
clinical disease [26]. Cockatiels can develop antibodies to PaBV as early as 6 days after 
experimental infection [147]. Most PaBV- antibodies are directed against N (P40), and 
have been identified in birds with recent or past infection. Anti-P and anti M were also 
detected but with greater variability, thus, these antibodies are less useful as markers for 
PaBV infection [27]. Currently, no studies that have looked for, or identified the 
presence of neutralizing antibodies in bornavirus-infected birds. In the case of BoDV-1, 
anti-G and anti M  neutralizing antibodies have been reported [148, 149]. Additionally, 
monoclonal antibodies directed toward the major glycoprotein (gp94) of BoDV-1 were 
capable of preventing Borna disease when given early in rats; a significant finding as 
regards vaccine development [150]. It seems that neutralizing antibodies might play a 
role in restriction of the infection into neural tissues in rats [149]. It has also been shown 
that anti-N and anti-P antibodies are non-neutralizing in the acute phase of Borna 
disease.  
 
In the case of PaBV infected psittacine birds, anti-G antibodies (C-terminal) as well as 
the antibodies against the L protein have never been detected, even in long-term 
persistently infected birds. This might be a result of the inability of recombinant proteins 
to interact with those antibodies, or the failure of the host to produce antibodies against 
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those proteins [27, 142]. These results are in partial agreement with BoDV-1 infection in 
mammals, where non-neutralizing antibodies can be abundantly detected as early as two 
weeks after experimental infection in rats whilst the neutralizing antibodies, if they 
develop at all, can only be detected late, during chronic, infection [150, 151]. 
 
There are several examples whereby specific virus-neutralizing antibodies (generated 
early after infection) play a major role against cytopathic viruses. These examples 
include poliovirus, rabies virus, influenza virus and vesicular stomatitis virus [152-155]. 
On the other hand, cellular immunity plays the dominant role in controlling the infection 
of noncytopathic viruses like BoDV-1 in rats, lymphocytic choriomeningitis virus in 
mice, human immunodeficiency virus, and hepatitis B and C viruses in humans [156-
159]. Thus, it is appears that in general, antibodies (humoral response) against PaBV in 
clinically infected birds are not protective, and in fact might be positively correlated with 
an increased severity of disease [18, 160].  
 
A strict correlation is not always observed between seroconversion, positive fecal PaBV-
RNA and virus load in tissues for the same bird [38, 109, 161]. A one year survey of 
naturally PaBV-infected psittacines from three bird collections revealed that PDD is 
more likely to develop in birds demonstrating high anti-PaBV antibodies in combination 
with a high PaBV RNA load in crop and cloacal swabs [161]. Additionally, some PDD- 
positive birds die in spite of high titer of antibodies against PaBV indicating that 
humoral immunity is not protective [161]. A similar result, mortality due to Borna 
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disease in the presence of  high anti-BoDV antibodies, was obtained from studies of 
immunocompetent rats [121]. 
 
Variable levels of anti-PaBV antibodies have been detected in egg yolk and serum of 
late-stage embryos hatched from PaBV-2 infected parents. Egg yolk immunoglobulin 
(Ig) Y composition reflected the IgG composition of serum antibodies from female 
parents. However, these antibodies were absent from hatchlings 2-5 weeks later which is 
similar to chickens [142, 162]. 
 
Additionally, there is little data on whether or not there is any cross-protection between 
different species of PaBV. In one experiment, healthy cockatiels naturally infected with 
PaBV-4 produced unusual and severe PDD- lesions after inoculation with a different 
strain of PaBV-4  [36]. 
 
Potential Therapy 
To date, the treatment of PDD is nonspecific and it is based on symptomatic treatment 
with supportive regimens; some treated birds have survived for months to years [163-
165]. Just a few studies have been published about the potential therapeutic effect of 
certain drugs [18, 25, 166]. On the other hand, antiviral therapy has never been reported 
as a successful treatment against PaBV infection [54, 119].  
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Since non-purulent inflammation is the pathognomonic histological lesion for PDD, 
several studies examined the therapeutic effects of anti- inflammatory drugs. 
Meloxicam, celecoxib and tepoxalin are non-steroidal anti-inflammatory drugs 
(NSAIDs) that have been recommended to reduce inflammation in PDD birds. 
Celecoxib (cyclooxygenase 2 inhibition) was reported as a candidate to treat PDD- 
affected birds (with improvement of the clinical signs), but this trial was done without 
using a control group [167, 168]. In one study, experimentally infected cockatiels were 
treated with meloxicam. In  that study, however, the treated cockatiels developed more 
severe lesions in comparison with control group in which cockatiels were PaBV positive 
but not treated [166]. 
 
Amantadine hydrochloride as an antiviral drug has been reported to reduce the clinical 
signs in PDD-affected birds [25, 168]. On the other hand, some researchers reported that 
amantadine hydrochloride has no effect on viral shedding of the infected birds [18]. 
Therefore, it’s unclear how this drug reduces the symptoms. Further studies need to be 
done to identify the mode of action [119]. Ribavirin was reported to reduce the infection 
of PaBV- infected cells in cell culture but had no measurable effect on viral shedding in 
infected birds [26]. 
 
As no antiviral drugs have been identified that can directly reduce infection by PaBV, it 
might be that the interruption of pathogenesis is a good therapeutic approach. Therefore, 
prevention of clinical disease by using immunosuppressive drugs such as cyclosporine A 
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was studied in mammals. Cyclosporine A (a T- cells – specific immunosuppressive 
drug) increased survival time, with no reported encephalitis or clinical symptoms, in 
experimentally infected rats [169]. Thus, similar treatment, of PDD in birds could be 
beneficial. In one case report, an African grey parrot suffering from PDD clinically 
recovered after administration of  cyclosporine A [170]. 
 
An immunomodulating therapeutic approach was suggested by some authors by using 
robenacoxib as an anti-COX-2 nonsteroidal anti-inflammatory drug in combination with 
Mycobacterium bovis extracts in order to re-direct activated T cells into local 
inflammatory sites.  However, these studies were done with no proper case-controls 
[147, 171], thus the results should be considered inconclusive. 
 
Many palliative therapeutic protocols have been used for the management of PDD- 
affected birds and responses could be evaluated by doing serial crop biopsies, detecting 
viral shedding in feces and/or radiographic imaging of the proventriculus [25, 168]. 
  
Development of a Vaccine for PDD  
Natural protective immunity to PaBV has not been demonstrated and there is no 
correlation between antibody levels and recovery. In fact, high antibody levels 
sometimes precede disease in persistently infected birds [170]. Studies of BoDV-1 
pathogenesis predict that some immune responses are directly linked to disease 
development [117, 122]. Therefore, it remains to be seen if vaccination is protective or 
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detrimental in experimental PaBV infection. Recently, one study described a vaccination 
strategy that reduced viral load in tissues, as well as bornavirus RNA shedding, in 
experimentally infected cockatiels and common canaries. These promising results were 
achieved by employing two viral vectors. Recombinant Newcastle disease virus and 
modified vaccinia virus Ankara were designed to express the nucleoprotein and 
phosphoprotein genes of PaBV-4 and canary bornavirus 2 (CnBV-2). These viral vectors 
demonstrated self-limiting infection in a prime/booster vaccination protocol and PaBV 
specific antibodies were detected in vaccinated birds [172]. These results showed for the 
first time that the bornavirus infection can be markedly reduced by vaccination, a very 
important step towards protection against PDD in psittacine birds [172]. A subsequent 
study from same authors indicated that using these vaccines via the same prime- boost 
vaccination regime in cockatiels protected against low dose PaBV-2 challenge  and 
development of PDD [145]. 
 
We have developed and tested inactivated whole virus and recombinant N protein 
vaccines in cockatiels as a part of our efforts to protect against PDD in parrots.  Even 
though vaccination with inactivated vaccine failed to stimulate humoral responses, one 
or two doses of recombinant N protein vaccine triggered anti N antibodies and protected 
vaccinated birds against PDD. QRT-PCR and IHC revealed that the recombinant N 
protein vaccine did not "efficiently" protect against infection. Based on these results, we 
hypothesized that protection against PDD in vaccinated birds occurred as a result of 
stimulation of Th2 responses and suppression Th1 responses. To test this hypothesis, we 
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used cyclosporine A as an immune suppressive drug. Indeed, the cyclosporine treated 
birds were protected against PDD. However, qRT-PCR also showed that the viral load 
was higher in the cyclosporine treated group. 
 
 30 
 
CHAPTER II  
MATERIALS AND METHODS 
 
Vaccines 
Inactivated whole virus and recombinant N- protein vaccines, as well as virus stocks for 
challenge were prepared in the Schubot Exotic Bird Health Center- in a BSL-2 
laboratory. 
 
Virus Culture and Quantitation 
PaBV-free primary duck embryo fibroblasts (DEF) were infected with a cockatiel 
(Nymphicus hollandicus) derived PaBV-2 isolate and cell cultures were passaged 7 
times. Focus forming unit (FFU) assays were used to determine the virus titer because 
bornaviruses are non- cytopathic both in vivo and in vitro [173-176]. FFU assays were 
performed, as described previously [177], with PaBV anti-N antibodies (1:500) as a 
primary antibody and alkaline phosphatase (AP)-conjugated goat anti-macaw IgY serum 
(Bethyl Laboratories TX, USA) as a secondary antibody. 
 
Inactivated Whole Virus Vaccine 
PaBV free primary DEFs were infected with a PaBV-2 isolate from cockatiels 
(Nymphicus hollandicus). Cells from passage 7, containing 6.5 x 105 FFU/ml of PaBV-2 
were suspended in phosphate-buffered saline (PBS). After brief sonication, the cell 
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suspension was inactivated by using formalin (36.5-38% in H2O), final concentration 
0.025%. Formalin treatment was done for 7 days. 
 
Recombinant N-Protein Vaccine 
Recombinant N protein was prepared as described previously [177].  Briefly, frozen 
brain tissue from a PaBV4- infected golden-collared macaw (Primolius auricollis) was 
used as source of viral RNA. RNA was extracted, using a Qiagen RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. In this 
protocol, the selective binding characteristics of a silica -based membrane were used to 
obtain up to 100 µg of RNA per sample. RNA was used to generate first-strand cDNA 
by reverse transcription (High Capacity Reverse Transcription Kit from Applied 
Biosystems Foster City, CA 94404 USA,) and random hexamers. PCR was performed to 
amplify the nucleoprotein gene of PaBV-4 (Accession number JN014948.1) using the 
following primers with BamHI and XhoI restriction enzyme sites added for cloning at 5’ 
and 3’ end respectively. 
 Forward primer for N cloning: 
 5’-CATG CAT ATG CCA CCC AAG AGA CAA AGA AGC (SEQ ID NO: 1)  
 Reverse primer for N cloning: 
 5’- GTAC CTC GAG GTT TGG GAA TCC GGT TAC ACC (SEQ ID NO: 2). 
The resulting PCR product was cloned into the TOPO™ cloning vector (Invitrogen™ 
Carlsbad, CA 92008 USA). E. coli cells were transformed and plasmids were prepared. 
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Plasmids were sequenced (Gene Technology Lab of Texas A&M University) using 
Sanger sequencing to confirm the correct sequence of the inserted PCR products.  
The N gene was moved into the pET 21a vector (Novagen™ Hornsby Westfield, NSW 
1635, Australia) to generate a histidine-tagged fusion protein. Bacterial cells containing 
the recombinant expression plasmid were grown and protein expression was induced 
with 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were harvested by 
centrifugation, resuspended in PBS buffer and sonicated. Sonicated material was 
centrifuged to remove insoluble product and the supernatant was applied to a Ni-NTA 
Agarose column (Qiagen, Hilden, Germany). The column was washed and eluted as 
recommended by the Qiagen manual. Material was then further purified by Sepharose 
CL-4B column chromatography. Purified protein preparations were analyzed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and WB. The purity of 
this protein was estimated to be greater than >95% pure by SDS-PAGE. Protein 
concentration was determined by using the BCA protein assay kit (Pierce, Rockford, IL).  
 
To prepare the vaccine, the protein concentration was adjusted to 25 µg per 75 µl of 
sterile saline. Each 0.1ml vaccine dose was contained 75µl of recombinant N protein in 
saline and 25µl alum (InvitrogenTM). Vaccine was administered by intramuscular 
injection into the right pectoral muscle. 
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Serological and Molecular Tests 
Western blot assays 
WB assays were used to assess anti-N antibody levels in plasma or serum collected at 
the following times: Before starting pilot, vaccine and vaccine safety experiments; three 
weeks after each vaccine dose (pilot and vaccine experiments) and at the end of each 
experiments (pilot, vaccine and cyclosporine A trials). For the vaccine safety trial, the 
second serum sample was collected 17 days after the booster dose of this vaccine. WB 
assays were performed as previously described [177]. Briefly, recombinant N- protein 
was adjusted to 1µg/ lane and electrophoresed on 10% polyacrylamide gels (size-
fractionation). Proteins were then transferred to polyvinylidene fluoride PVDF (in 
transfer buffer, consisted of Trizma base (Sigma), glycine, H2O and methanol, at 90 V 
for 1.5 hr.) and the membrane blocked with 5% nonfat dry milk in phosphate buffered 
saline (PBS) plus 0.05% Tween 20 for two hrs. at room temperature. Membranes were 
incubated with diluted bird sera (1:200) for two hrs. at room temperature followed by: 
Washing for three times, ten minutes each, with wash buffer (0.02 M sodium phosphate 
(Na2HPO4·7H2O), 0.15 M sodium chloride (NaCl), pH 7.2 and 0.05% (v/v) Tween-20. 
Membranes were then incubated for one hr. at room temperature with alkaline 
phosphatase labeled goat anti-macaw IgY (Bethyl Laboratories, Montgomery, TX). 
diluted 1:5000 in blocking buffer. Membranes were then rinsed three times for 10 min 
each with washing buffer and developed using 5-bromo-4-chloro-3-indolyl phosphate/p-
nitroblue tetrazolium chloride (BCIP/NBT) from Sigma (St. Louis, Missouri, USA) and 
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air dried for 30 min before reading. Sera from histopathological-PDD positive parrots, 
diluted 1:5000 in PBST blocking buffer, was used as a positive control. 
 
Quantitative real-time PCR (qRT-PCR) 
This test was performed to detect the presence and relative quantity of viral RNA in 
tissues from test birds. Cloacal swabs were taken at various times to assess levels of 
virus shedding. Tissues were collected at necropsy and frozen at-80°C. RNA was 
extracted from tissue samples and cloacal swabs using RNeasy Mini Kits and QIAapm 
viral RNA mini kits respectively (Qiagen, Hilden, Germany). Extracted RNA from 
cockatiel samples were analyzed using a qRT-PCR assay targeting the P gene of PaBV. 
qScript XLT One-Step RT-qPCR ToughMix ROX (Eurofins company, Val Fleuri, 
Luxembourg) was used to carry out First-strand cDNA and PCR amplification in a 
single tube. Each reaction contained TaqMan probe and primers:  
ABV P9F primer-5_-AAGAAGAA[Y]CC[Y]TCCATGATCTC-3_ (36 μM). 
ABV P10R primer-5_-AA[Y]TGCCGAAT[B]A[R]GTCATC-3_ (36 μM). 
ABV P TaqMan 
Probe-5_FAM-TCGATAACTG [Y]TCCCTTCCGGTC-3_-BHQ (10 μM). 
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Avian β actin was used as housekeeping gene for the purpose of quantitating the viral 
load for qPCR. Actin primers were also used to check the success of RNA extraction 
using. Actin mRNA was amplified using the following primers and probe (Integrated 
DNA Technologies, Coralville, IA, USA): 
 
Actin F (5’- CATGAA GATCCTGAC AGA-3’) 
 Actin R (5’-TCTCCTGCTCYA AYTCCA-3’). 
 Actin probe (5’-/56FAM/CACCACCACAGCCGAGAGAGAAAT/3BHQ-1/-3’). 
QPCR was carried out using the ABI (Foster City, CA 94404 USA) 7900HT Fast Real-
Time PCR system with SDS 2.4 software. The amplification profile was:  
1 cycle: 5 min 50°C (reverse transcription), 1 cycle: 20 sec 95°C (RT inactivation/initial 
denaturation), 45 cycles: 3 sec 95°C (PCR denaturation), 30 sec 56°C (PCR annealing). 
Threshold cycle values (Ct) >35.0 were considered negative [13] . Relative change in 
gene expression (mRNA of P gene) was determined using the 2 - ΔCt method, with beta 
actin used as the endogenous control [178, 179]. 
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Immunohistochemistry (IHC) 
 IHC was performed to determine the distribution of PaBV antigen in tissues. This test 
was done according to method of Wunschmann et al. [180]. An automated staining 
process was used to perform IHC using polyclonal antiserum against PaBV- N protein 
(strain 1367; GenBank accession no. FJ169440). This antiserum was used as primary 
antibody. Briefly: Sections of four-micron thickness were placed on glass slides and then 
were deparaffinized (clearing agent) and rehydrated (alcohol 100%, 95%, 70%, and 50% 
distilled H2O) then incubated with 3% H2O2 for 15 min to block the activity of 
endogenous peroxidase. Tris buffered saline with 0.05% Tween 20 was used to rinse the 
sections.  These sections then were incubated with normal goat serum diluted 1:10 in 
TBST for blocking unspecific binding sites. Sections were then incubated with anti-
PaBV antiserum (diluted 1:1,250) for 45 min at room temperature. Sections were 
washed with TBST and were then incubated with secondary antibody (polymer-labeled 
goat anti-rabbit immunoglobulin G in 2% normal chicken serum) for 45 min at room 
temperature. Positive antigen–antibody reactions were developed with 3-amino-9-
ethylcarbazole (AEC) for 10 min. Slides were briefly counterstained with Mayer 
hematoxylin. Sections were analyzed and reactions were graded as mild, moderate and 
severe according to the number of PaBV antigen–positive cells. IHC examination was 
done blindly by an expert pathologist in the California Animal Health & Food Safety 
Laboratory System (H. Shivaprasad, Pers Comm) 
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Virus for Challenge and Experimental Infection 
PaBV-2 isolate from cockatiels was grown in primary DEF monolayers as described 
previously [74, 177]. DEF were passaged 5 times. The virus titer was determined by 
counting FFU as described previously [177]. Virus preparations were adjusted to a 
concentration of 4 x 104 FFU of PaBV-2 per 0.1 ml saline [177]. Each bird was 
inoculated intramuscularly (0.1 ml) with this virus with the exception of the cyclosporine 
A experiment where each bird was inoculated with 8 x 105 FFU.  
 
Samples of each inoculum (0.5 ml) of infected DEFs were retained for further 
cultivation to ensure that the birds were given viable virus. All birds were kept in 
isolation rooms in a facility at the College of Veterinary Medicine and Biomedical 
Sciences avian complex / Texas A&M University under the Biosafety Level 2 (BSL2).  
(Although PaBV has never been shown to infect humans, bornaviruses have been 
reported to cause neuropsychiatric disorders of humans [181] and we have recently 
demonstrated that PaBV is infectious for cultured human astrocytes). Birds were housed 
in flight cages, food and water were provided ad libitum. 
Experimental infections were performed under Animal Use Protocol IACUC 2012-0266 
approved by the Texas A&M University Institutional Animal Care and Use Committee. 
In general, any birds that lost 20% of their body weight were euthanized using CO2 
under isofluorane anesthesia. 
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Experimental Animals and Study Design 
Pilot experiment 
For the pilot experiment, twenty-six adult male and female cockatiels (Nymphicus 
hollandicus) were clinically healthy and tested free from herpesvirus, chlamydia and 
PaBV. Herpesvirus and chlamydia tests were performed by an external diagnostic 
laboratory. WB and RT-PCR assays were performed in-house on plasma and cloacal 
swabs to detect antibody and PaBV RNA, respectively. All these birds tested negative 
for both PaBV RNA and antibodies. 
 The birds were divided into three groups: 
 
Group 1A consisted of 9 birds. Each bird was vaccinated with a single priming dose, 
followed by two booster doses (three weeks apart) of inactivated whole virus vaccine 
administered IM, 0.1 ml/bird. Inocula contained 6.5 x 105 FFU of PaBV-2. Based on 
western blot results, this group was subsequently given a dose of recombinant N- protein 
vaccine intramuscularly (25 µg/ bird) one month after the second booster dose of 
inactivated vaccine. Western blots were used to detect the presence of anti-PaBV 
antibodies in the birds in this group. The WB antigen consisted of recombinant N 
protein. Serum from a PaBV-free cockatiel was used as a negative control. 
All birds in this group were challenged with PaBV (4 x 104 FFU/ bird) one month after 
receiving the recombinant N protein vaccine. 
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Group 1B consisted of 9 birds. These birds received no vaccine. They were challenged 
on the same day as birds in Group 1A (0.1 ml/bird containing 4 x 104 FFU/ bird of 
PaBV-2).  This group was used to determine the virulence of the challenge virus as a 
control.  
 
Group 1C consisted of 8 birds. These birds were challenged on the same day as birds in 
groups 1A and 1B. However, these birds were additionally given one dose of 
recombinant N protein vaccine 30 DPC. 
Birds in all groups were monitored for 200 DPC, at which time all remaining birds were 
euthanized. 
 
Recombinant N protein vaccine study 
For this, study we used twenty male and female cockatiels. All tested negative for PaBV 
(RNA and antibodies), herpesvirus and chlamydia (as described above) and were divided 
into two equal groups. 
 
 Group 2A birds were vaccinated with one prime and one booster dose (21 days apart) of 
recombinant N protein vaccine (25 µg/ bird). One month later birds were challenged 
with PaBV-2 (4 x 104 FFU/ bird) administered IM. 
 
Group 2B birds received no vaccine, but were challenged with virus as described above 
for group 2A. All birds were monitored for 200 days post challenge.  
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Cyclosporine A experiment 
Sixteen adult male and female cockatiels were divided into two equal groups:   
Group 3A birds were given a dose (0.2 mg/bird) of cyclosporine A, suspended in sesame 
oil via the oral route daily for 70 days (study period). These birds were challenged with 
PaBV-2 given by IM route 24 hours after the cyclosporine A treatment began. The dose 
of virus used was 8 x 105 FFU/ bird. 
 
Group 3B birds were given sesame oil throughout the 70 days study period as a control 
for the stress of daily handling Group 3A birds. Group 3B birds were challenged as 
described above for group 3A. A higher challenge dose of virus was used in this study 
due to the shortened observation period. 
 
Differential counts of white blood cells (WBC): All the birds in the cyclosporine A study 
were bled via jugular venipuncture (~0.05 ml) and approximately three blood smears 
were prepared without anticoagulant. The blood smears were rapidly air dried and then 
fixed with methanol. Slides were submitted to the clinical pathology laboratory at Texas 
A&M university, College of Veterinary Medicine for Modified Wright’s staining prior 
to differential leucocyte counts. 
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Vaccine safety trial 
Fifty adult male and female cockatiels tested negative for the presence of anti PaBV 
antibodies using WB assays before starting this experiment. The majority of these birds 
had shed PaBV at least once during the last few years, as indicated by results of PCR on 
cloacal swabs. Each bird was given two doses of recombinant N protein vaccine, 26 days 
apart, administered by the IM route and tested for anti-PaBV antibodies after the second 
dose. The birds were monitored daily for six months for any adverse reaction that might 
have occurred due to the vaccine. 
 
 Pathology 
The vaccine experiments continued for 200 DPC and the cyclosporine A experiment for 
70 DPC. During this time, birds were visually monitored on a daily basis. Initial weights 
were taken 2-3 DPC and every 7-14 days thereafter. Any bird that lost more than 20% of 
its original weight in addition to any PDD - related clinical signs was euthanized. 
Complete necropsies were performed on each bird whether euthanized or died for other 
reasons. Tissue samples collected included:  
Brain, eye, optic nerve, spinal cord, peripheral nerves, lung, heart, liver, spleen, 
pancreas, adrenal gland, kidney, gonad, crop, proventriculus, ventriculus, intestine, 
cloaca, skin and a portion of the pectoral muscle. Tissues samples were placed in 10% 
buffered formalin and embedded in paraffin for histopathologic examination. 
Hematoxylin and eosin stains were used to stain 4 µm tissues sections. Bright field 
microscopy was used to examine the stained slides. 
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 Histopathology examination was done blindly by an expert pathologist in the California 
Animal Health & Food Safety Laboratory System (H. Shivaprasad) or at the Texas 
A&M Veterinary Medical Diagnostic Laboratory. 
 No cockatiels in the safety trial died or were euthanized for any reason, through the 
observation period.  
 
Statistical Analysis 
One-way analysis of variance (ANOVA) with the subsequent Tukey's HSD (honest 
significant difference) in addition to Unpaired and Paired t tests were performed using 
GraphPad Prism software version 7.02 to analyze differences between groups in respect 
to mean body weight and for quantification of viral load in organs and cloacal swabs as 
well as relative semi-quantification analysis of ImageJ software results of WB assays. 
p<0.05 was considered significant differences. 
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CHAPTER III  
RESULTS 
 
Pilot Experiment 
This pilot experiment was conducted to answer the following questions: 
• Is it possible to demonstrate an immune response in birds vaccinated with a cell-
associated, inactivated whole virus vaccine? 
• Is this response protective against virus challenge? 
• Does the response exacerbate disease in birds in which protection is incomplete? 
• Does the response exacerbate disease in previously naïve birds? 
• Does the response exacerbate disease in previously infected (healthy) birds? 
Three groups of PaBV-negative cockatiels (seronegative and negative for PaBV 
shedding) were used. Group 1A consisted of 9 birds vaccinated with 3 doses (one prime 
and two boosters) of formalin inactivated PaBV-infected duck embryo fibroblasts 
(DEF). 
 
Group 1A (vaccinated group) birds were tested for antibodies against PaBV N protein 3 
weeks after each booster dose of inactivated vaccine and all were negative by western 
blot assay (Fig. 2).  
As we were unable to detect an immunologic response to the inactivated vaccine, Group 
1A birds were subsequently inoculated with a single dose of recombinant N protein 
vaccine.  
 44 
 
The rationale for changing the pilot experimental design was that we did not wish to 
challenge birds in which we were unable to measure an immune response. In response to 
the single dose of recombinant N protein vaccine, 7 of 9 birds in Group 1A 
seroconverted (were western blot-positive for anti PaBV N antibodies) by 3 weeks (Fig. 
2), thus the experiment was continued and the questions were revised: 
• Is it possible to demonstrate an immune response in birds vaccinated with a cell-
associated, inactivated whole virus vaccine followed by a dose of recombinant N 
protein vaccine? 
• Is this response protective against virus challenge? 
• Does the response exacerbate disease in birds in which protection is incomplete? 
• Does the response exacerbate disease in previously naïve birds? 
• Does a dose of recombinant N protein vaccine exacerbate or protect previously 
infected birds? 
 
 
 
 
 
 
 
 
 
 45 
 
 
 
 
 
 
A   
 
          
      
B 
         
 
 
 
Figure 2. Western blot assay for the pilot study vaccine group. (A) Vaccine group after 
the second booster dose of inactivated whole virus vaccine. (B) Vaccine group after one dose of 
recombinant N protein vaccine. M= size marker. C = positive control serum. The black arrow 
denotes the location of PaBV- N protein. R= test repeated. 
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Experimental infection, clinical observations and pathology 
To test for vaccine efficacy, Groups 1A, 1B and 1C were challenged, on the same day 
with 4 x 104 FFU of PaBV-2 by the intramuscular route. All birds were observed daily 
and all were weighed at regular intervals. The birds in Group 1A survived, and were 
apparently healthy through 200 days post challenge (DPC) (Fig. 3). In contrast, many of 
the birds in Group 1B and 1C, lost weight and sickened, and died. In Group 1B, 7 of 9 
birds died or were euthanized before 200 DPC due to PDD- related poor health (Table 
1). In Group 1C (vaccinated- post challenge group), 5 of 8 birds also sickened and died 
or were euthanized before 200 DPC due to PDD- related poor health. 
 Body weights of all birds were recorded 2-3 DPC and then every 10-14 days through 
200 DPC. Average group body weights at each time point are shown in Fig. 4.  There 
was variability within each group, however the overall trend was that birds in Groups 1B 
and 1C initially lost weight, but that the long-term survivors in these two groups had 
weights comparable to those of the vaccinated birds by the end of the observation period. 
The average weights at all time points were then used to determine if there was an 
overall difference between vaccinated and the control groups. This was accomplished 
using Tukey's HSD (Fig. 5). The difference in overall average weight over the whole 
experiment, between vaccinated (1A) and the control group (1B) was significant at 
p<0.05 (Fig. 5). There was no significant difference between Group 1C and the other 
two groups. 
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Figure 3. Survival curves for pilot study. Percent survival was calculated for each group. 
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Figure 4. Mean body weight of pilot study birds.  marks viral shedding in ≥ 50 % of the 
birds. ∆ marks mortality in ≥ 50% of the birds. 
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Figure 5. Scatterplot of body weights for pilot study. Mean ± SE.  P = 0.0066 
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Table 1. Macroscopic & Microscopic PDD-related lesions from pilot study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group 1A: vaccinated, Group 1B: unvaccinated control, Group 1C: vaccinated post challenge. 
Macroscopic lesion= Included not limited to enlarged dilated proventriculus. Microscopic 
lesion= marked lymphoplasmacytic ganglioneuritis and encephalitis or encephalomyelitis. Pos. = 
positive; Neg. = negative. DPC= days post challenge. 
 
 
 
 
Group  Bird # Macroscopic  Microscopic  Time point of 
death/euthanasia (DPC) 
1A 62 
70 
38 
40 
39 
69 
34 
43 
37 
Neg. 
Neg. 
Pos. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Pos. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
200 
200 
200 
200 
200 
200 
200 
200 
200 
1B 48 
60 
57 
50 
45 
64 
68 
65 
61 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
40 
41 
49 
59 
62 
69 
153 
200 
200 
1C  44 
54 
63 
59 
51 
58 
36 
49 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
Neg. 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Neg. 
Pos. 
Neg. 
40 
41 
48 
55 
100 
200 
200 
200 
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During the study period, all the vaccinated birds (Group 1A) were clinically healthy; 
none displayed any PDD- related clinical signs. Moreover, most of these birds showed 
no gross lesions characteristic of PDD upon necropsy (Table 1) with the exception of 
bird #38 that had a mildly dilated proventriculus.  In contrast to the vaccinated group,  
 birds in Group 1B (unvaccinated control) and 1C (vaccinated post-challenge) showed 
gastrointestinal clinical signs of PDD, in particular, apathy, emaciation and undigested 
seeds in the feces. Necropsy of these birds revealed the presence of typical lesions of 
PDD which included a dilated proventriculus. The exceptions were two birds from 
Group 1B (# 60 and 61) and three birds from Group 1C (#54,58 and 49). 
In Group 1B, 7of 9 birds died or were euthanized due to PDD prior to 200 DPC. One of 
the two surviving birds also had signs of infection and developing PDD upon necropsy. 
In the vaccinated post-challenge group, 5of 8 cockatiels died or euthanized due to PDD. 
Of the 5 birds in groups 1B and 1C that survived the challenge, two had a dilated 
proventriculus and three others had flaccid hearts, enlarged crops and/or severe enteritis 
when necropsied at 200 DPC. 
 
Histopathological examination of birds from Group 1A (vaccinated group) revealed only 
1 of 9 with lesions (lymphoplasmacytic ganglioneuritis and encephalitis) suggestive of 
PDD (Table 1). Bird #38 had mild to moderate perivascular cuffing and increased glial 
cells in brain, with a few scattered lymphoid nodules in and around the serosa and 
isolated ganglia of the proventriculus, gizzard, and intestine.  
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The heart had focal infiltration of lymphocytes around isolated epicardial ganglia. In 
contrast, all birds from the control group (1B) and 6 birds from Group 1C (vaccinated 
post challenge) had lesions typical of PDD, ranging from mild to severe multifocal 
perivascular cuffing and gliosis randomly scattered throughout brain. In addition, 
infiltration of lymphocytes mixed with a few plasma cells in the subserosal layers of the 
myenteric plexus in the proventriculus and gizzard was noted along with formation of 
lymphoid nodules.  
 
As summarized in Table 1, all birds in Group 1B displayed either macroscopic or 
microscopic lesions, thus morbidity was 100%. Mortality by 200 DPC was 78% in this 
group. In Group 1C, morbidity was 75% and mortality by 200 DPC was 62.5%. This is 
in contrast to the vaccinated birds (Group 1A) in which morbidity was 11% and 
mortality was 0%. 
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Detection of PaBV-RNA in cloacal swabs and organs 
qRT-PCR was used to detect and quantify PaBV-RNA (P gene mRNA) in cloacal swabs 
(Table 2) and several organs (Table 3). Most birds shed viral RNA at least once during 
the study period. Exceptions included one bird (# 45) from Group 1B and two birds (#44 
and #59) from Group 1C. Those birds died or were euthanized relatively early, before 63 
DPC. Within these two groups there was no correlation between shedding and survival 
as non-shedders died at 62, 40 and 55 DPC while, all clinically healthy birds in group 
1A shed virus by day 84.  Of the 5 survivors from groups 1B and 1C, all shed virus at 
one or more time points. Each bird was tested for the presence of PaBV- RNA in seven 
organs (brain, crop, proventriculus, ventriculus, heart, kidney and adrenal gland). The 
results are summarized in Table. 3. At least one organ from each bird was positive for 
PaBV-RNA except one bird (#65) from Group 1B (survived the study period of 200 
DPC) in which all the examined tissue samples were negative. In contrast, although all 
birds in Group 1A (vaccinated) survived for 200 DPC (and 8 of 9 had no gross lesions) 
all had high levels of PaBV-RNA in all tested organs (Table. 3). With the exception of 
bird #65, the other 5 surviving birds from groups 1B and 1C had high levels of PaBV 
RNA in their organs. Tukey's HSD revealed significant differences at p<0.05 for the 
viral RNA load in the ventriculus between the vaccinated group and both the control and 
vaccinated post challenge groups and for the kidney, between vaccinated group and 
control group (Fig. 6). However, the results were not significant at p<0.05 for the 
vaccinated birds in comparison with other 2 groups when only the survivors of each 
group were compared. 
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Table 2. Results of qRT-PCR in cloacal swabs from pilot study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group 1A: vaccinated, Group 1B: unvaccinated control, Group 1C: vaccinated post challenge. 
Scoring in term of threshold cycle values as follows:  Neg., > 35; +, 35 to 30; ++ 30 to 25; +++, 
25 to 20; ++++, 20 to 15; +++++, 15 to 10. 
Neg.= negative. DPC, days post challenge. a= at death/euthanasia. 
 
 
 
 
 
 
 
Group Bird # Time point of cloacal swabs (DPC) Time point of 
death/euthanasia 
(DPC) 
52 84 125 200 
1A 62 
70 
38 
40 
39 
69 
34 
43 
37 
++ 
Neg. 
++ 
+ 
Neg. 
Neg. 
Neg. 
Neg. 
+ 
++++ 
+++ 
++++ 
++ 
+++ 
+ 
++++ 
+++ 
+++ 
++++ 
++++ 
+++ 
++++ 
+++ 
+++ 
++++ 
+++ 
+++ 
++++ 
++++ 
+++ 
++++ 
++++ 
++++ 
+++ 
+++ 
+++ 
200 
200 
200 
200 
200 
200 
200 
200 
200 
1B 48 
60 
57 
50 
45 
64 
68 
65 
61 
++a 
++a 
+++a 
+ 
Neg. 
+ 
Neg. 
Neg. 
Neg. 
 
 
 
+++a 
Neg.a 
Neg.a 
+ 
Neg. 
+ 
 
 
 
 
 
 
+ 
+ 
+ 
 
 
 
 
 
 
+a 
Neg. 
+++ 
40 
41 
49 
59 
62 
69 
153 
200 
200 
1C 44 
54 
63 
59 
51 
58 
36 
49 
Neg.a 
+++a 
+++a 
Neg. 
Neg. 
++ 
++ 
Neg. 
 
 
 
Neg.a 
++ 
+++ 
++++ 
+++ 
 
 
 
 
+++a 
+++ 
+++ 
++++ 
 
 
 
 
 
+++ 
+++ 
+++ 
40 
41 
48 
55 
100 
200 
200 
200 
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Table 3. Results of qRT-PCR and IHC in organs from pilot study. 
 
Group  Bird 
# 
                                                     Tissue  Time point of 
death/eutha-
nasia (DPC) 
Brain  Crop  Provent-
riculus  
Ventric-
ulus  
Heart  kidney  Adrenal 
gland 
1A  62 
70 
38 
40 
39 
69 
34 
43 
37 
++++s 
+++++s 
++++s 
+++++s 
+++++s 
++++s 
++++mo 
+++++s 
+++++mo 
+++++mo 
+++++mo 
+++++s 
+++++mo 
+++++mo 
++++mo 
++++nt 
++++mo 
+++++mo 
+++++s 
+++++s 
+++++s 
+++++s 
+++++s 
+++++mo 
+++++mo 
+++++s 
+++++mo 
+++++s 
+++++s 
+++++s 
++++s 
+++++s 
+++++mo 
++++mo 
++++s 
++++mo 
++++nt 
++++nt 
++++ng 
++++mo 
+++++s 
++++mi 
++++s 
++++nt 
+++++mi 
+++++nt 
+++++s 
+++++ng 
+++++nt 
++++s 
++++nt 
+++++mi 
+++++nt 
+++++mi 
++++nt 
++++nt 
+++++nt 
++++nt 
++++nt 
++++nt 
++++nt 
++++nt 
++++ng 
200 
200 
200 
200 
200 
200 
200 
200 
200 
 
 Brain  Crop  Provent-
riculus  
Ventric-
ulus  
Heart  Kidney  Adrenal 
gland 
 
1B 48 
60 
57 
50 
45 
64 
68 
65 
61 
++mi 
+++s 
+++s 
+++++mo 
++ng 
+++mo 
++++mi 
Neg. ng 
++++s 
++mi 
+++mi 
+++mi 
+++mo 
Neg.ng 
++ng 
++ ng 
Neg. ng 
++++mo 
+++mi 
+++mo 
++++mo 
+++mo 
Neg. ng 
Neg. ng 
++ ng 
Neg. ng 
++++s 
+++mi 
+++mo 
++++mo 
+++mo 
Neg. ng 
++ ng 
+++ ng 
Neg. ng 
++++s 
+++ng 
Neg. mo 
+nt 
+++nt 
++ng 
Neg. nt 
++ ng 
Neg. ng 
++ nt 
++ng 
+++nt 
++ng 
+++ng 
Neg. nt 
++ nt 
+++ ng 
Neg. nt 
++++ nt 
+++nt 
++++mo 
++++ng 
++++mi 
++nt 
+++ nt 
+++ mi 
Neg. nt 
++++ nt 
40 
41 
49 
59 
62 
69 
153 
200 
200 
 
 Brain  Crop  Provent-
riculus  
Ventric-
ulus  
Heart  Kidney  Adrenal 
gland 
 
1C  44 
54 
63 
59 
51 
58 
36 
49 
++ ng 
+++s 
++++ mi 
++++ mo 
+++++mo 
+++++ s 
++++mo 
+++s 
+++ ng 
+++ nt 
++ ng 
++ ng 
++++ ng 
+++++mo 
++++mo 
++++mo 
+++ ng 
+++s 
++++ ng 
Neg. ng 
+++ mi 
+++++ s 
+++++mo 
+++++s 
++ ng 
+++s 
+++ ng 
Neg. ng 
+++ mi 
+++++ s 
+++++mo 
+++++s 
Neg. ng 
Neg. nt 
Neg. nt 
Neg. ng 
++ ng 
++++ mo 
+++++nt 
++++nt 
Neg. nt 
Neg. ng 
Neg. ng 
Neg. ng 
+++ ng 
++++mo 
+++++nt 
++++mo 
Neg. nt 
+++ mi 
++++ mi 
+++ nt 
+++ mo 
+++++nt 
++++nt 
+++++nt 
40 
41 
48 
55 
100 
200 
200 
200 
 
Group 1A: vaccinated, Group 1B: unvaccinated control, Group 1C: vaccinated post challenge. 
Scoring in term of threshold cycle values as follows:  Neg., > 35; +, 35 to 30; ++ 30 to 25; +++, 
25 to 20; ++++, 20 to 15; +++++, 15 to 10. 
Neg. = negative. IHC= immunohistochemical staining: ng = negative; mi = mild; mo = 
moderate; s = severe; nt = not tested. DPC, days post challenge. 
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Immunohistochemistry 
 As summarized in Table 3, PaBV-N antigen was detected by immunohistochemistry 
(IHC) in at least one of the following organs: Brain, crop, proventriculus, ventriculus, 
heart, kidney and adrenal gland from all the birds except two from Group 1B (#65 and 
45) and one from Group 1C (#44), that were not tested for the presence of viral antigen 
in kidney and adrenal. Note that bird #65 was also negative for PaBV-RNA by PCR. 
Additional tissues from Group 1A birds were also examined. These included intestine, 
lung, liver, gonad, skin, cloaca, eye, peripheral nerves and skeletal muscle. One or more 
than one of these tissues were positive from each bird revealing, the widespread 
presence of viral antigen, in the absence of lesions. Some of these tissues were also 
positive in birds from Group 1B and 1C, in particular those that survived the challenge, 
(however not all birds were tested for these tissues). IHC staining for PaBV-N antigen 
was scored as mild, moderate or severe for each organ (Table 3). All vaccinated birds 
demonstrated mild to strong reactions for PaBV-N antigen in several organs. Severe IHC 
results were scored for the brain, proventriculus, and ventriculus in 6 of 9 vaccinated 
birds, despite the fact that they were negative for gross and/or histopathological lesions 
typical of PDD. The exception was bird #38. Consistent with the PCR results, large 
amounts of antigen were present in 44 of 47 PCR positive samples for Group 1A birds. 
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Figure 6. Results of qRT-PCR in organs from pilot study. A: Scatterplot of delta Ct 
values; horizontal lines represent the mean ± SE. for each organ. B: Fold changes. Differences 
were considered significant when P < 0.05 by ANOVA and Tukey's HSD. 
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Figure 6. Continued. 
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Detection of antibodies against PaBV 
 All of the vaccinated birds (Group 1A) had developed antibodies to PaBV N by the end 
of the experiment, as indicated by western blots using sera collected at necropsy. All of 
the vaccinated post challenge birds (Group 1C), both those that were euthanized due to 
PDD prior to 200 DPC and those that survived for 200 DPC were seropositive (Fig. 7). 
Among 7 tested Group 1B birds, all were also positive for antibodies to PaBV N. 
Therefore, in this experiment, development of an anti-N antibody response prior to 
challenge did not protect Group 1A birds from infection.   
 
ImageJ software was used to analysis relative WB band density and the results were not 
significant at p<0.05 (ANOVA and Unpaired t tests) either between groups or for the 
birds which survived and were euthanized 200 DPC versus those euthanized before 200 
DPC due to PDD (the control and vaccinated post challenge groups) (Fig. 8). 
A paired t test also revealed that the level of antibodies to PaBV N 3 weeks after the 
recombinant N protein vaccine were not significantly different (at p<0.05) than levels at 
200 DPC (Fig. 9) at the group level. However, it is interesting to note that 3 birds in the 
vaccinated group (#40, 43 and 34) had reduced levels of anti-N antibody compared to 
their pre-challenge level. 
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Figure 7. Western blot assay for the pilot study 200 DPC. (A) Vaccine group. (B) 
Control group. (C) Vaccine post challenge group. M= size marker. C = positive control serum. 
Black arrow = denotes the location of PaBV- N protein.    
    = euthanized before the end of the experiment. 
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Figure 8. Semi quantification analysis of WB assays for the pilot study using 
ImageJ software. = euthanized before the end of the experiment. 
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Figure 9. Semi-quantification analysis of WB assay for pilot study vaccinated group 
using ImageJ software.  
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Recombinant N Protein Vaccine  
Based on results of the pilot experiment we next sought to determine if protection from 
disease (Group 1A birds in the pilot experiment) could be obtained using a recombinant 
N vaccine alone. This experiment used two groups: 2A, vaccinated (10 birds) and 2B, 
unvaccinated-control (10 birds). All the birds were seronegative by WB before starting 
this experiment. All tested negative for PaBV-RNA fecal shedding by PCR. Three 
weeks after receiving the first dose of recombinant N vaccine (25 µg per bird 
intramuscularly), birds were assayed for seroconversion and 4 of 10 were positive by 
WB (Fig. 10). A second dose (booster dose) of this vaccine was given to all birds in the 
N-vaccine group and they were tested after another 3 weeks. At this time, all birds were 
seropositive by WB against the recombinant N protein (Fig. 10).  
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Figure 10. WB assay for vaccine experiment. (A) Vaccine group after first dose of 
recombinant N protein vaccine. (B) Vaccine group after second dose of recombinant N protein 
vaccine. M= size marker. C= positive control serum. Black arrow denotes the location of PaBV- 
N protein.     
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Experimental infection 
Vaccinated and unvaccinated-control birds were challenged IM with 4 x 104 FFU of 
PaBV-2 and following challenge the birds were observed daily until the experiment was 
terminated at 200 DPC. 
 
 The first death occurred at 32 DPC (bird#341) in the unvaccinated control group. In 
contrast, none of the vaccinated birds died except bird #311 which died at 44 DPC (Fig. 
11). Birds in the unvaccinated group lost a significant amount of weight (Fig. 12) and 
were in general less active than birds in the N-vaccine group. By 100 DPC, 3 more birds 
in the unvaccinated control group died. In all, 6 of 10 unvaccinated control birds died or 
were euthanized due to PDD before the end of the experiment, at 200 DPC.  Within the 
vaccinated group the only death was at 44 DPC and the remainder of the birds remained 
clinically healthy. Mean body weights of all birds were recorded at the beginning of the 
challenge and every 10-14 days until 200 DPC. Unpaired t tests revealed that weight 
differences were significant (p=0.0009) between the vaccinated and the control group 
(Fig13). 
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Figure 11. Survival curves for vaccine experiment. Percent survival was calculated for 
each group. 
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Figure 12. Mean body weight of vaccine experiment.   marks viral shedding in ≥ 50% 
of the birds.  marks mortality in ≥ 40 % of the birds. ∆ marks mortality in ≥ 50% of the birds. 
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Figure 13. Scatterplot of individual body weights for vaccine study. Mean ± SE. P = 
0.0009 
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Clinical observations and pathology 
During the 200 day observation period, all vaccinated birds were clinically healthy 
except bird #311 (died at 44 DPC). This bird was emaciated and undigested seeds were 
found in its feces, thus PDD was-suspected. Indeed, necropsy revealed a mildly dilated 
proventriculus. All remaining vaccinated birds were necropsied at day 200 PC (Table 4). 
At this time, one bird (#333) had a mildly dilated proventriculus.  In contrast, birds in the 
unvaccinated group (2B) showed a variety of signs of PDD including apathy, weight loss 
and undigested seeds in the feces. Upon necropsy, all birds in this group (with the 
exception of #318) revealed typical lesions of PDD (Table 4) including a dilated 
proventriculus (Fig. 14). In summary, macroscopic analysis revealed 2 of 10 vaccinated 
birds with mild PDD like symptoms or lesions while 9 of 10 unvaccinated birds had 
gross lesions consistent with a diagnosis of PDD. 
 
Histopathological examination (Table 4) of birds from the vaccinated group showed no 
lesions suggestive of PDD (lymphoplasmacytic ganglioneuritis and encephalitis) (Fig. 
15) except birds #311 and 333. Examination of tissues from bird #311 showed 
infiltration of a few lymphocytes and occasional plasma cells in and around the 
subserosal nerves/ganglia of the proventriculus and gizzard. Bird #333 had limited (one 
section) focal perivascular cuffing in brain and crop; the proventriculus and gizzard had 
mild to moderate infiltration of lymphocytes and a few plasma cells in the serosal and 
subserosal ganglia. In contrast, in the unvaccinated group, 8 of 10 birds showed different 
degrees of PDD- related microscopic lesions. 
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 In brain sections, there were scattered mild to severe multifocal perivascular cuffing and 
gliosis (Fig. 15). Subserosal layers of the myenteric plexus in the proventriculus (Fig. 
16) and gizzard (Fig. 17) also showed infiltration of lymphocytes mixed with a few 
plasma cells and some formation of lymphoid nodules. 
 
 
 
 
 
Figure 14. Proventriculus from control challenged bird. Severely dilated, thin 
proventriculus, indicative of PDD. P= proventriculus, V= ventriculus, H= heart, L= liver 
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Table 4. Macroscopic & Microscopic PDD-related lesions from vaccine experiment. 
 
 
 
 
 
 
 
Group 2A: vaccinated, Group 2B: unvaccinated control. 
Macroscopic lesion= Included not limited to enlarged dilated proventriculus. Microscopic 
lesion= marked lymphoplasmacytic ganglioneuritis and encephalitis or encephalomyelitis. 
Pos. = positive; Neg. = negative. DPC= days post challenge. 
 
 
 
 
 
 
Group  Bird # Macroscopic  Microscopic  Time point of 
death/euthanasia (DPC) 
2A 311 
395 
396 
338 
188 
333 
323 
394 
393 
376 
Pos. 
Neg. 
Neg. 
Neg. 
Neg. 
Pos. 
Neg. 
Neg. 
Neg. 
Neg. 
Pos. 
Neg. 
Neg. 
Neg. 
Neg. 
Pos. 
Neg. 
Neg. 
Neg. 
Neg. 
44 
200 
200 
200 
200 
200 
200 
200 
200 
200 
2B 341 
375 
336 
334 
317 
318 
339 
322 
335 
340 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
Pos. 
32 
89 
99 
106 
161 
192 
200 
200 
200 
200 
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Figure 15. Histological and immunohistochemical staining findings in brains of 
vaccine experiment birds. A: Brain from vaccinated bird with no significant PDD- related 
lesions revealed by H&E staining. B: Brain from control bird with extensive perivascular 
mononuclear cuffing revealed by H&E staining. a: Positive IHC staining for PaBV antigen in 
brain from A. b: Positive IHC staining for PaBV antigen in brain from B.  
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Figure 16. Histological and immunohistochemical staining findings in 
proventriculus of vaccine experiment birds. A: Proventriculus from vaccinated bird with 
no significant PDD- related lesions revealed by H&E staining. B: Proventriculus from control 
bird with myenteric ganglioneuritis revealed by H&E staining. a: Positive IHC staining for PaBV 
antigen in proventriculus from A. b: Positive IHC staining for PaBV antigen in proventriculus 
from B.  
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Figure 17. Histological and immunohistochemical staining findings in ventriculus of 
vaccine experiment birds. A: Ventriculus from vaccinated bird with no significant PDD- 
related lesion revealed by H&E staining. B: Ventriculus from control bird with myenteric 
ganglioneuritis and formation of lymphoid nodules revealed by H&E staining. a: Positive IHC 
staining for PaBV antigen in ventriculus from A. b: Positive IHC staining for PaBV antigen in 
ventriculus from B.  
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Detection of PaBV-RNA in cloacal swabs and organs 
qRT-PCR was used to detect the presence of the PaBV-RNA in cloacal swabs (Table 5) 
and several organs (Table 6). Cloacal swabs were collected at 6 time points (Fig.18). 
Most of the birds shed the virus at least once during the study period of 200 DPC. Bird 
#341 from the unvaccinated group, who died, at 32DPC, was the only negative 
individual in the group. Bird #311 from the vaccinated group died at 44DPC before a 
fecal swab was collected. Bird #340 in the unvaccinated group was also negative 
throughout the 200 days of the study. 
 
Birds were also tested for the presence of PaBV-RNA in tissue samples. Seven organs 
were tested (brain, crop, proventriculus, ventriculus, heart, kidney and adrenal gland). 
Among the unvaccinated group, no birds were entirely free of PaBV. However, #339 
and #340, which survived the challenge, had only 1 positive organ each. Other birds in 
this group had high levels of viral RNA.  
 
In the vaccinated group, #311 (died at 44 DPC) had a positive brain and ventriculus. 
Five additional birds were strongly PCR positive at 200 DPC. Bird # 395 had one organ 
positive, its brain. Three birds (#338, #394 and #393) were PCR negative for all 
examined tissues. A t test was performed and revealed significant differences at p<0.05 
between vaccinated and control groups for crop and heart tissues (Fig. 19).  
While no other tissues showed a significant difference between the two groups, the clear 
trend was that the vaccinated birds had higher levels of viral RNA in their tissues. 
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Immunohistochemistry 
Six of 10 of vaccinated birds were IHC positive (moderate to severe) for PaBV-N 
antigen (Table 6) (Figs. 15-17), of which, 4 had severe levels of staining in the brain. 
Five of 6 positive birds showed no gross and/or histopathologically lesions normally 
attributed to PDD. A sixth bird, #333, had such lesions. Four birds in the vaccinated 
group (#311, #338, #394, #393) were IHC negative for all organs tested. In all birds 
except #311, PCR and IHC results were well correlated. In the unvaccinated control 
group (Fig. 15-17) birds #341 and #340 were IHC negative for all tissues tested; 
however, both birds were PCR positive in 1 or 2 tested organs.  
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Table 5. Results of qRT-PCR in cloacal swabs from vaccine experiment. 
 
Group Bird #       Time point of cloacal swabs (DPC) Time point of 
death/euthanasia 
(DPC) 
49 98 106 153 183 200 
2A 311 
395 
396 
338 
188 
333 
323 
394 
393 
376 
nt. a 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
++++ 
 
Neg. 
++++ 
Neg. 
Neg. 
++ 
Neg. 
Neg. 
Neg. 
++++ 
 
Neg. 
++++ 
Neg. 
Neg. 
+ 
+ 
Neg. 
+ 
++++ 
 
Neg. 
++++ 
Neg. 
Neg. 
+++ 
++++ 
Neg. 
Neg. 
+++ 
 
++++ 
Neg. 
Neg. 
Neg. 
+++ 
Neg. 
++++ 
++++ 
Neg. 
 
Neg. 
+++ 
++ 
++ 
++ 
+++ 
++ 
Neg. 
+++ 
44 
200 
200 
200 
200 
200 
200 
200 
200 
200 
2B 341 
375 
336 
334 
317 
318 
339 
322 
335 
340 
Neg. a 
Neg. 
+ 
+ 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
 
+ a 
++ 
+++ 
++ 
Neg. 
Neg. 
+ 
++ 
Neg. 
 
 
++++a 
+++ 
+++ 
Neg. 
+ 
++ 
++ 
Neg. 
 
 
 
+++ a 
+++ 
++ 
Neg. 
+++ 
+++ 
Neg. 
 
 
 
 
+++ a 
Neg. 
+++ 
++++ 
++++ 
Neg. 
 
 
 
 
 
+++ a 
Neg. 
++++ 
+++ 
Neg. 
32 
89 
99 
106 
161 
192 
200 
200 
200 
200 
Group 2A: vaccinated, Group 2B: unvaccinated control. 
Scoring in term of threshold cycle values as follows:  Neg., > 35; +, 35 to 30; ++ 30 to 25; +++, 
25 to 20; ++++, 20 to 15; +++++, 15 to 10. Neg.= negative. DPC, days post challenge. a= at 
death/euthanasia. nt= not tested. 
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Table 6. Results of qRT-PCR and IHC in organs from vaccine experiment. 
 
Group  Bird 
# 
                                                     Tissue  Time point of 
death/eutha-
nasia (DPC) 
Brain  Crop  Provent-
riculus  
Ventric-
ulus  
Heart  kidney Adrenal 
gland 
 
2A 311 
395 
396 
338 
188 
333 
323 
394 
393 
376 
++ ng 
++++ mo 
+++ s 
Neg. ng 
++++ s 
++++ s 
+++++mo 
Neg. ng 
Neg. ng 
+++++ s 
Neg. nt 
Neg. ng 
++++ mo 
Neg. ng 
+++ s 
++++ mo 
+++++ nt 
Neg. ng 
Neg. ng 
++++ mo 
Neg. ng 
Neg. ng 
++++ mo 
Neg. ng 
+++ s 
++++ mo 
+++++mo 
Neg. ng 
Neg. ng 
++++ s 
++ ng 
Neg. ng 
++++ mo 
Neg. ng 
+++ s 
++++ mo 
++++mo 
Neg. ng 
Neg. ng 
++++ s 
Neg. ng 
Neg. nt 
+++ nt 
Neg. nt 
+++ mi 
+++ mi 
+++ nt 
Neg. nt 
Neg. nt 
+++ nt 
nt 
Neg. nt 
++++ nt 
Neg. nt 
+++ mi 
++++ nt 
++++ nt 
Neg. nt 
Neg. nt 
++++ nt 
nt 
Neg. nt 
+++ nt 
Neg. nt 
++++ nt 
++++ nt 
++++ nt 
Neg. nt 
Neg. nt 
+++ nt 
44 
200 
200 
200 
200 
200 
200 
200 
200 
200 
 
2B  341 
375 
336 
334 
317 
318 
339 
322 
335 
340 
+++ ng 
+++++ s 
++++ s 
+++++ s 
+++++ s 
++++ s 
Neg. ng 
++++ s 
+++++ s 
++ ng 
Neg. nt 
++ mo 
++++ mo 
++++ mo 
++++ mo 
++++ mi 
Neg. ng 
+++ mi 
++++ mo 
Neg. ng 
++ ng 
+++ mo 
++++mo 
++++ s 
++++ mo 
++++ mi 
Neg. ng 
++++ mo 
+++ mo 
Neg. ng 
Neg. ng 
+++ mo 
+++++mo 
+++++ s 
++++ mo 
++++ mi 
Neg. ng 
+++ mo 
+++ mo 
Neg. ng 
Neg. nt 
++ nt 
+++ mi 
+++ nt 
++++ nt 
++ nt 
Neg. nt 
++ nt 
++ nt 
Neg. nt 
Neg. ng 
+++ nt 
++++ nt 
++++ nt 
++++ nt 
++++ 
mo 
Neg. nt 
+++ nt 
++++ nt 
Neg. nt 
+ nt 
+++ nt 
++++ nt 
+++ nt 
++++ nt 
++++ nt 
+ mi 
++++ nt 
++ mi 
Neg. nt 
32 
89 
99 
106 
161 
192 
200 
200 
200 
200 
 
Group 2A: vaccinated; three birds were negative. Group 2B: unvaccinated control. 
Scoring in term of threshold cycle values as follows:  Neg., > 35; +, 35 to 30; ++ 30 to 25; +++, 
25 to 20; ++++, 20 to 15; +++++, 15 to 10. 
Neg. = negative. IHC= immunohistochemical staining: ng = negative; mi = mild; mo = 
moderate; s = severe; nt = not tested. DPC, days post challenge. 
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Figure 18. Fold changes in virus shedding, qRT-PCR of cloacal swabs, at different 
time points post challenge from vaccine experiment. Right Y axis represents results of 
the first time cloacal swabs were taken. Vaccine group shed less virus than control group at day 
106 and 183 post challenge. 
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Figure 19. Results of qRT-PCR in organs from vaccine study. A: Scatterplot of delta Ct 
values; horizontal lines represent mean for each organ. B: Fold changes. Difference is significant 
when P < 0.05. t test 
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Figure 19. Continued  
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Detection of antibodies against PaBV 
All vaccinated birds were seropositive after two doses of recombinant N vaccine (Fig. 
10) and the results of WB analysis using ImageJ software were analyzed using a paired t 
test. There was a significant difference (p<0.05) in WB reactivity between first and 
second dose of recombinant N vaccine.  
 
All vaccinated birds remained seropositive, by WB, on day 200 PC (Fig. 20). All tested 
control birds (four euthanized after 200 DPC and three euthanized before 200 DPC) 
became seropositive by WB (Fig. 20). The results were not significant at p<0.05 
(Unpaired t test) between the two groups. Moreover, there was no significant difference 
within control birds that survived 200 DPC or were euthanized before 200 DPC due to 
PDD (Fig. 21). 
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 B 
        
 
Figure 20. WB assay for vaccine experiment 200 DPC. (A) Vaccine group. (B) Control 
group. * denotes birds euthanized before the end of the experiment. M= size marker. C = positive 
control serum. Black arrow denotes the location of PaBV- N protein. 
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Figure 21. Semi quantification analysis of WB assay for the vaccine experiment. 
Using ImageJ software. = euthanized before the end of the experiment.       
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Cyclosporine A Experiment 
Based on the result of N protein vaccination, we performed this experiment to 
investigate the possibility that PDD might be an immune mediated disease. In particular, 
we were interested in the role of T cells in the development of PDD. Therefore, we used 
cyclosporine A, administered daily, to suppress T cell responses. Two groups of 8 
cockatiels each were challenged with virulent PaBV-2. Group 3A birds were treated 
daily with cyclosporine A and Group 3B birds were given the vehicle alone (sesame oil).  
WBC differential counts, done with blood collected 29 days after the experiment began, 
revealed that mean lymphocyte counts were lower in birds in the cyclosporine A treated 
group in comparison with the control group. However, the difference was not significant 
at p<0.05 (Fig.22). 
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Figure 22. Cyclosporine A experiment, comparing percent blood lymphocytes. 
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Clinical observations and pathology 
All the birds were challenged with 8 x 105 FFU of PaBV-2 24 hours after the 
cyclosporine A treatment began. Through the study period of 70 DPC, none of the 
cyclosporine A treated birds (Group 3A) showed any clinical signs related to PDD and 
all these birds survived the challenge (Fig. 23). On the other hand, birds in Group 3B 
were less active and the majority lost weight in comparison to Group A (Fig.24). Weight 
differences were compared using an unpaired t test and were significant p<0.05 between 
the two groups (Fig.25). 
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Figure 23. Survival curves for the cyclosporine A experiment. Percent survival was 
calculated for each group. 
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Figure 24. Mean body weights of cyclosporine A experiment groups. ∆ marks 
mortality in ≥ 50% of the birds. 
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Figure 25. Scatterplot of body weights for cyclosporine A experiment. Mean ± SE. 
 P = 0.0486  
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In Group 3B, 6 of 8 birds died or were euthanized before the end of the experiment; 
upon necropsy, 7 of 8 birds had a dilated proventriculus. In contrast, no Group 3A birds 
showed gross lesions related to PDD (Table 7).  
 
Histopathological examination revealed that only one bird (#388) from Group 3A had 
microscopic lesions. Bird #388 had marked lymphocytic inflammation within the nerve 
ganglia in the muscular tunics of the proventriculus and ventriculus in addition to 
perivascular lymphocytic encephalitis in brain (Table 7). In contrast, 6 of 8 birds from 
Group 3B showed microscopic PDD lesions which included lymphocytic ganglioneuritis 
in the proventriculus and ventriculus as well as lymphocytic perivascular encephalitis. 
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Table 7. Macroscopic & Microscopic PDD-related lesions from cyclosporine A 
experiment. 
 
Group  Bird # Macroscopic  
lesion 
Microscopic  
lesion 
Time point of 
death/euthanasia (DPC) 
3A   3703 
W  
388 
390 
666 
384 
36 
381 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
 
Neg. 
Neg. 
Pos. 
Neg. 
Neg. 
Neg. 
Neg. 
Neg. 
70 
70 
70 
70 
70 
70 
70 
70 
3B 626 
378 
387 
386 
385 
3750 
389 
22 
 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Neg. 
 
Neg. 
Pos. 
Pos. 
Pos. 
Neg. 
Pos. 
Pos. 
Pos. 
 
42 
43 
56 
56 
65 
67 
70 
70 
Group 3A: Cyclosporine A treated, Group 3B: Untreated control. Macroscopic lesion= 
Included not limited to enlarged dilated proventriculus. Microscopic lesion= marked 
lymphoplasmacytic ganglioneuritis and encephalitis or encephalomyelitis. Pos. = 
positive; Neg. = negative. DPC= days post challenge. 
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Detection of PaBV-RNA in organs 
qRT-PCR results of brain, proventriculus and ventriculus showed that the viral load was 
higher in treated birds (Group 3A) in comparison with control birds (Group 3B) (Table 
8). The results were analyzed using an unpaired t test and were significant p<0.05 
between these two groups for brain and proventriculus only (Fig. 26).   
 
Detection of antibodies against PaBV 
WB assays were performed on all cyclosporine A treated birds (sera collected upon 
necropsy at 70 DPC) and on 5 of 8 control birds (three of these were euthanized before 
70 DPC due to PDD and two survived through 70 DPC).  Among 8 tested Group 1A 
birds, only three were seropositive. In contrast, all tested Group 1B birds were 
seropositive (Fig. 27). The results were not significant at p<0.05 (t test) between 
cyclosporine A treated birds and the controls, however the results were significant 
between birds that survived the challenge and those euthanized before the end of this 
experiment for the control group (Fig.28). 
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Vaccine Safety Trial 
 Two doses of recombinant N vaccine were given for 50 cockatiels without subsequent 
challenge to assess any potential risk. 
 
All 50 cockatiels were clinically healthy through the six months observation period and 
none of them died or showed any adverse reaction due to two doses of recombinant N 
vaccine. Western blot assays revealed that 77-80% of those birds were seropositive after 
the second dose of recombinant N protein vaccine. 
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Table 8. Results of qRT-PCR in organs from cyclosporine A experiment. 
 
Group  Bird # Tissue Time point of 
death/euthanasia 
(DPC) 
Brain  Proventriculus  Ventriculus  
3A 3703 
W  
388 
390 
666 
384 
36 
381 
++++ 
++++ 
+++++ 
+++++ 
++++ 
++++ 
+++++ 
++++ 
+++++ 
+++++ 
++++ 
+++++ 
+++++ 
+++++ 
+++++ 
++++ 
+++++ 
+++++ 
++++ 
+++++ 
++++ 
++++ 
++++ 
++++ 
70 
70 
70 
70 
70 
70 
70 
70 
 
  Brain  Proventriculus  Ventriculus   
3B  626 
378 
387 
386 
385 
3750 
389 
22 
++ 
++++ 
++++ 
++ 
++ 
+++ 
+++ 
+++ 
Neg. 
+++ 
++ 
Neg. 
+++ 
++ 
Neg. 
+++ 
Neg. 
+++ 
+++ 
++ 
+++ 
Neg. 
Neg. 
+++ 
42 
43 
56 
56 
65 
67 
70 
70 
Group 3A: Cyclosporine A treated, Group 3B: None treated control. 
Scoring in term of threshold cycle values as follows:  Neg., > 35; +, 35 to 30; ++ 30 to 25; 
+++, 25 to 20; ++++, 20 to 15; +++++, 15 to 10. 
Neg. = negative. DPC, days post challenge. 
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Figure 26. qRT-PCR in organs from cyclosporine A experiment. A: Scatterplot of 
delta Ct values; horizontal lines represent mean for each organ. B: Fold changes. Difference is 
significant when P < 0.05. t test 
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Figure 26. Continued. 
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 B  
        
 
Figure 27. WB assay for cyclosporine A experiment. Unless noted, sera were collected at 
70 DPC. (A) Cyclosporine A treated. (B) Untreated control. M= size marker. C = positive 
control serum. Black arrow denotes the location of PaBV- N protein. *= euthanized before the 
end of the experiment. 
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Figure 28. Semi quantification analysis of WB results for the cyclosporine A 
experiment using ImageJ software.    
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CHAPTER IV  
DISCUSSION AND CONCLUSIONS 
 
Even though PDD was first described as a fatal disease of captive parrots more than 40 
years ago, and the first PaBVs were identified more than 8 years ago [1, 12, 13], many 
questions remain about the disease and the virus. Many infected birds are clinically 
healthy carriers and the triggers of disease are unknown; natural routes of transmission 
are suspected to be fecal-oral but this has not been demonstrated experimentally; vertical 
transmission of PaBV is suspected but has not been formally demonstrated either; it is 
not known with what frequency infected birds clear an infection. In addition, detecting 
infection is difficult as some birds shed virus very infrequently and many birds fail to 
produce antibody. Finally, the pathogenesis of PDD is suspected to be immune-
mediated, as is well-established for mammalian bornavirus infections [31, 119, 182], 
however this has not been formally determined. 
 
In studies using Lewis rats, immunization with recombinant N protein resulted in 
exacerbation of Borna disease [183]. This result was despite the fact that BoDV-1 N 
protein is the most abundantly expressed viral protein in infected cells and triggers 
strong immune responses [184, 185]. This result could potentially confound vaccine 
development. However, the results of this project show, for the first time, evidence for 
the protective efficacy and effectiveness of a recombinant N protein vaccine to prevent 
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development of PDD in challenged birds. These studies, further indicate that PDD is 
indeed, an immune mediated disease. 
 
Two vaccine experiments performed in cockatiels in which inactivated PaBV and/or 
PaBV recombinant N protein vaccines were used. Following challenge with virulent 
PaBV, the disease course was monitored over the period of 200 days. Additionally, a 
study using cyclosporine A as an immunosuppressive agent was done to investigate the 
potential pathogenesis of this disease. Finally, a safety study for the recombinant N 
protein vaccine was also performed.  
 
 In the first (pilot) experiment, all the birds were seronegative for anti PaBV-N 
antibodies as tested by WB assay before started this experiment. All the vaccinated birds 
(group 1A) remained seronegative after an initial dose and two booster doses of 
inactivated whole virus vaccine. It should be noted that the titer of PaBV in DEF is low, 
even when most cells in the culture are positive for PaBV antigen. In addition, little virus 
is released into the supernatant in this noncytopathic infection [48, 186, 187]. The low 
quantity of viral antigen, in comparison to cellular antigens likely contributed to the lack 
of a detectable anti-N response. The ideal for an inactivated whole virus vaccine is a 
high titer virus preparation, harvested from culture supernatant, purified and inactivated 
[188]. However, three weeks after administration of a single dose of recombinant N 
protein vaccine, over 70% (7/9) of cockatiels previously given 3 doses of inactivated 
vaccine were positive for anti-N antibodies providing some evidence that the inactivated 
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virus preparation had indeed primed the immune response. Another contributing factor 
to the failure of the inactivated vaccine to induce detectable antibodies might be loss 
immunogenicity due to the use formalin for inactivation. This has been reported for Rift 
Valley fever virus and bovine herpes virus-1 when formalin was used to inactivate these 
agents [189, 190]. None of the vaccinated birds (9/9) showed any clinical signs 
suggestive of PDD throughout the period of 200 DPC. Only one bird, #38, had a mildly 
dilated proventriculus upon necropsy, and histopathological examination revealed mild 
to moderate perivascular cuffing in the brain. In contrast, most birds in the unvaccinated 
and vaccinated post-challenge groups developed clear signs of PDD. 
  
The most surprising result of both vaccine trials was that, despite lack of clinical disease, 
all vaccinated, infected, birds had levels of viral RNA and antigen comparable to the 
control (unvaccinated) group suggesting that protection from disease was in fact due to 
administration of recombinant N. Of the 19 vaccinated birds of two experiments, 3 from 
the second experiment appeared to have been protected from infection, as evidenced by 
virus negative tissues at necropsy. In contrast, all of the unvaccinated birds had some 
evidence of infection. Thus, it is possible that the N vaccine protected some birds against 
infection. Perhaps more important and encouraging was the observation that the 
vaccinated, infected birds remained healthy, suggesting that the anti-N response was not 
immunopathogenic. In contrast, several rodent trials were failed to generate protection 
against Borna disease by using N protein viral vector vaccines and sometimes the 
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clinical disease was exacerbated as it is difficult task to generate protective immunity 
against an immune- mediated disease without exacerbating it [123, 183].  
These findings suggest that a better vaccine protocol might be developed, with the aim 
of achieving higher levels of protection against infection and with little risk of 
immunopathogenesis in those birds that are virus positive prior to vaccination or in 
instances where protection from infection is not complete. 
 
It should also be noted that vaccinated birds received a ‘relatively high’ challenge dose 
of virus (delivered by the IM route) in comparison to another study in which successful 
persistence infection and development of clinical disease was achieved in 2 of 4 
cockatiels by giving them as little as 102.7 FFU of PaBV-2/ bird via parenteral 
route[145]. Moreover, the investigators failed to achieve persistence infection via the 
mucosal route (peroral and oculonasal) even when 500-fold dose of the same challenge 
was used [145]. Therefore, we may have seen better protection from infection were the 
challenge dose lower, and administered by a more ‘natural’ route. Unfortunately, other 
groups have failed to reliably infect cockatiels by oro-nasal routes [145]. Thus, defining 
a biologically relevant challenge remains problematic. Future vaccine trials with 
recombinant N would also benefit from development of an anti-N ELISA with high 
specificity and sensitivity so that levels of vaccine induced antibodies might be 
correlated to protection against challenge. It is clear however that in infected birds, an 
anti-N response does not protect from disease as there was no correlation between 
antibody levels and survival or disease development. 
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The results of a safety trial of the recombinant N vaccine also encourage further 
development, as 50 cockatiels previously exposed to PaBV in an aviary setting, 
remained healthy after receiving 2 doses of the recombinant N vaccine. 
 
The induction of protection from the development of PDD by using recombinant N 
protein vaccine was unexpected as in essence, most PDD- affected birds (natural or 
experimental infection) have anti N antibodies, indicating that this disease can develop 
despite an antibody response [18, 25, 110, 146, 161]. Moreover, it has been 
demonstrated that even high levels of neutralizing antibodies do not prevent persistent 
infection and the development of Borna disease in rodents models [121, 182]. 
Bornaviruses are non-cytopathic both in vivo and in vitro [176, 182, 191]. Borna disease 
in mammals is well known as an immune mediated disease caused by cellular immune 
responses, in particular CD8+ T cells [182]. Both, humoral and cellular immune 
responses target the N protein of this virus [184, 185]. However, several rodent vaccine 
studies failed to generate protection against Borna disease using N protein viral vector 
vaccines and some cases clinical disease was exacerbated [123, 183]. In contrast 
however, Henkel et al [117] demonstrated that Lewis rats were protected from the 
challenge with BoVD-1 by vaccination with a recombinant parapoxvirus vector 
expressing BoVD-1- N. Furthermore, it seems that induction of immunity against 
BoVD-1 depends on anti-viral mechanisms of non-cytolytic CD8+ T-cells as MRL mice 
(wild type and perforin-deficient) can be protected by vaccination with a recombinant 
parapoxvirus vector expressing BoVD-1 N followed by a vaccinia virus vector 
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expressing BoVD-1 N [122]. It appears that cytokines produced by brain- infiltrating 
CD8+ T cells, in particular IFN- gamma and TNF-alpha, are responsible for virus 
clearance, without causing severe neuronal damage [122, 192, 193]. So, it is clear that 
virus-specific CD8+ T cells can mediate either viral clearance or the immune mediated 
pathogenesis typical of this disease [122]. A delicate balance must be maintained 
regarding virus replication, vaccination and responses of virus- specific T cells in order 
achieve protection [122].  
 
 The results presented here support a role for immune- mediated pathology in the 
development of PDD. We propose that vaccination with recombinant N in alum favored 
the development of Th2 humoral responses that protected these birds from the 
development of clinical PDD. Use of recombinant PaBV N protein eliminates any 
immune responses to a vector, which might be interfere with protective immune 
responses directed against N [117]. Use of alum as an adjuvant may have induced Th2 
humoral immune responses in the absence of IL-4- or IL-13-mediated signaling, but may 
also have suppressed Ag-specific Th1 responses [194, 195].  Our proposal is supported 
by results of BoDV-1 infections of Lewis rats [196] where authors suggested that a  
switch from Th1 cellular immune responses in the acute phase of BoDV1- infected 
Lewis rats, to a Th2 humoral immune response in chronic phase of disease was 
correlated with survival in association with decreased inflammation in the CNS [196]. 
Subsequent studies also revealed that IgG locally produced in CNS of experimentally 
infected Lewis rats in the chronic phase of Borna disease influences BoDV1- gene 
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expression and pathogenesis [197]. Based on these results we hypothesize that our 
vaccine might have suppressed the cytolytic and the non-cytolytic activities of PaBV- 
specific CD8+ T cells as disease did not develop in vaccinated birds, despite the 
presence of viral RNA and viral antigen in numerous organs. 
 
 At the current time, the reagents to dissect immune responses in cockatiels are not 
available. However, cyclosporine A is well known to inhibit cytotoxic T lymphocytes 
responses [198, 199]. Therefore, we assessed the ability of cyclosporine A to prevent 
PDD in birds challenged with virulent PaBV. Indeed, the cyclosporine A treated birds 
remained healthy during the observation period. As was observed with vaccinated birds, 
the cyclosporine A treated birds were infected and produced virus. In fact, their viral 
load was higher than control (challenged) birds. These results are the strongest indication 
to date that PDD may develop as a result of T cell- mediated immunopathogenesis and 
that the same cells might be responsible for restricting virus replication.  
 
 Given variable results with vaccination of rodents against BoDV-1 and the likelihood of 
immune mediated pathogenesis of PDD, we expected to see enhanced disease among 
cockatiels immunized with recombinant PaBV N protein. However, we saw the opposite 
effect; protection against disease in conjunction with increased virus replication and 
distribution. Therefore, we designed and performed a vaccine experiment using only 
recombinant N protein vaccine. The experiment confirmed that protection against the 
development of clinical PDD did not require priming by the inactivated whole virus 
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vaccine administered in the pilot study. In general, the results of the N vaccine 
experiment were similar to the first experiment as regarding protection against the 
development of PDD. However, three vaccinated birds were negative for viral RNA and 
viral antigen in their organs, an indication that there may have been a protective (against 
infection) component provided by the N vaccine. 
 
At the end of the N vaccine experiment, tested control birds (7/9) were seropositive 
regardless of different time points of death or euthanasia. The majority of these birds 
suffered from PDD in contrast to the vaccinated birds. Together, these results indicate 
that there is no correlation between the humoral immunity and the protection from PDD. 
 
Intermittent viral RNA shedding also was noted for birds in both vaccine studies, 
however, in the second experiment, viral shedding was lower in vaccine group than in 
the control group in two of six times points (Fig.18). This might be due to the fact that 
two doses of recombinant N vaccine were not only enough for the protection from 
clinical PDD but also lower viral load in cloacal swabs by stimulating the noncytolytic 
CD8+ T cells. This was demonstrated for other neurotropic viruses like Sindbis virus 
and flaviviruses where antiviral non-neutralizing antibodies clear the virus from the 
brain by prevention or restriction gene expression of the virus [200-203]. Moreover, 
binding of antibodies to the surfaces of infected cells might lead to activation of 
intracellular signaling pathways which in turn attracted T- cells and activate microglia 
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which might lead to viral clearance as result of IFN-γ or TNF-α production [200, 201, 
204, 205]. 
 
In all, the present study provides for the first time that the recombinant N protein vaccine 
can protect against the development of clinical PDD as a result of a switch from a Th1 
cellular immune response to a Th2 humoral immune response. 
 
Conclusions and Future Studies 
Conclusions of the studies presented herein include: 
• A vaccine prepared from recombinant PaBV N protein in alum is safe and elicits 
a specific antibody response. 
• A recombinant N vaccine, used as described herein, does not efficiently prevent 
infection with an IM challenge of virulent PaBV. 
• The recombinant N vaccine, used as described herein provides effective 
protection from clinical disease. Use of this vaccine reduced both morbidity and 
mortality among experimentally infected cockatiels. This result was supported by 
a lack of microscopic lesions in the vaccinated, challenged cockatiels. However, 
vaccinated birds became persistently infected.  
• In vaccinated, PaBV challenged cockatiels, there was no apparent correlation 
between anti-N antibody titers and susceptibility to infection and/or disease 
development. 
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• There is no indication that the recombinant N vaccine, used as described herein, 
enhances disease in PaBV infected cockatiels. 
• Unvaccinated, PaBV challenged cockatiels developed variable antibody 
responses, with no apparent correlation with morbidity or mortality. 
• The presence of viral RNA and antigen in vaccinated, challenged cockatiels, 
along with a lack of immune infiltrates in tissues, suggested an immune-mediated 
component to PDD. 
• Cyclosporine A treatment of cockatiels effectively prevents clinical PDD in 
PaBV challenged individuals. The lack of macroscopic and microscopic lesions 
in cyclosporine A strongly supports an immune mediated pathogenesis for PDD. 
 
Many questions remain regarding protection against the disease and/or infection with 
PaBV. We suggest the following studies: 
 
• Development of a more natural PaBV infection model, mimicking conditions of 
natural infection, to provide a more realistic test of vaccine efficacy.  
• Changing vaccine dose and administration schedule in an effort to improve 
protection against infection. 
• Producing a vaccine with additional viral proteins, such as G, alone or in 
combination with N to achieve greater protection from PaBV infection. 
• Maintaining vaccinated, PaBV infected birds for longer periods (up to a year) to 
monitor disease development and/or clearance of the virus. 
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• Maintaining cyclosporine A treated, challenged birds, for longer periods (up to a 
year) to monitor disease development and/or clearance of the virus. 
• Determine the most efficient, yet effective cyclosporine A treatment schedule for 
experimentally infected birds. 
• Determine the effects of cyclosporine A treatment using controlled trials with 
naturally infected birds.  
• Develop reagents to identify T cell subsets in cockatiels and other parrots in 
order to determine the mechanism(s) of immune-mediated disease development. 
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